: The AMEDEO Literature Guide

Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Lung Cancer

Free Subscription

Articles published in Lung Cancer
Retrieve available abstracts of 751 articles:
HTML format

Single Articles

April 2027

CHO BC, Lim SM, Lee SH, Kim DK, et al
MORPHEUS-Lung: biomarkers and clinical response to atezolizumab + bevacizumab + stereotactic body radiotherapy in patients with metastatic non-small cell lung cancer.
Lung Cancer. 2027 Apr 16:109354. doi: 10.1016/j.lungcan.2026.109354.
PubMed Abstract available

June 2026

ZHAO L, Li F, Zhu Z, Zhao J, et al
Meta-analysis of cutaneous immune-related adverse events in NSCLC: Accounting for treatment heterogeneity and immortal time bias.
Lung Cancer. 2026;216:109422.
PubMed Abstract available

MURATA S, Kashima J, Horinouchi H, Kishikawa S, et al
Comparative analysis of therapeutic target protein expression in de novo and transformed small cell lung carcinomas using paired biopsy samples.
Lung Cancer. 2026;216:109418.
PubMed Abstract available

ZHOU N, Tsui S, Toumbacaris N, Tan KS, et al
Utilization of invasive mediastinal nodal staging and prevalence of occult nodal disease in patients with synchronous primary lung cancers.
Lung Cancer. 2026;216:109420.
PubMed Abstract available

XU K, Tan B, Liang R, Liang J, et al
DNA methylation biomarkers-based method for the differential diagnosis of multiple lung cancers.
Lung Cancer. 2026;216:109415.
PubMed Abstract available

KENMOTSU H, Niho S, Tsuboi M, Wakabayashi M, et al
Five-year overall survival in JCOG1205/1206: irinotecan or etoposide plus cisplatin for resected high-grade neuroendocrine carcinoma of the lung.
Lung Cancer. 2026;216:109386.
PubMed Abstract available

HORNE A, Gomez-Randulfe I, Ford A, Milton R, et al
Navigating controversies in stage III NSCLC: a multidisciplinary case discussion on evolving treatment paradigms.
Lung Cancer. 2026;216:109411.
PubMed Abstract available

PASELLO G, Pigato G, Mulargiu C, Ferrarini F, et al
Dissecting the prognostic role of metabolic markers in lung neuroendocrine Tumors: The MONET study.
Lung Cancer. 2026;216:109404.
PubMed Abstract available

KLOK JM, Kaplan ZLR, Paats MS, Eijkelboom AH, et al
Regional variations in molecular testing and treatment of patients with metastatic NSCLC in the Netherlands.
Lung Cancer. 2026;216:109406.
PubMed Abstract available

CHIARI R, Russano M, Leva G, Emili R, et al
A multicenter prospective study of single nucleotide polymorphisms in the PDCD1 (programmed cell death 1) gene in patients with metastatic lung adenocarcinoma treated with pembrolizumab.
Lung Cancer. 2026;216:109383.
PubMed Abstract available

LIN JX, Yin K, Yan LX, Zhu Y, et al
First case report of transformation of adenocarcinoma to adenosquamous carcinoma with giant-cell carcinoma harboring HER2 mutation after zongertinib (BI 1810631) resistance.
Lung Cancer. 2026;216:108912.
PubMed Abstract available

RUITER G, Le X, Soo RA, Yamamoto N, et al
Emerging treatment strategies for HER2-mutant NSCLC: Striving for selectivity, efficacy, and tolerability.
Lung Cancer. 2026;216:109378.
PubMed Abstract available

RGN JY, Taylor S, Faivre-Finn C, Perry MB, et al
New conversations in an old argument: Lessons learnt from the PIONEER randomised feasibility study in resectable stage III-N2 NSCLC.
Lung Cancer. 2026;216:109387.
PubMed Abstract available

May 2026

KO JJ, Blais N, Brade A, Clelland C, et al
Consensus recommendations on surveillance and survivorship for patients with unresectable/stage IV non-small cell lung cancer after completing Immunotherapy: a Delphi study by Canadian experts.
Lung Cancer. 2026;217:109455.
PubMed Abstract available

MUDUMBA R, Liu X, Jin S, Davis IJ, et al
Comparative effectiveness of first-line targeted therapies in ALK-positive non-small cell lung cancer: real-world evidence of tyrosine kinase inhibitors.
Lung Cancer. 2026;217:109451.
PubMed Abstract available

SUN Z, Xin W, Tian Y, Lu S, et al
Treatment patterns of elderly patients with limited-stage small-cell lung cancer in real-world data: A multicentre retrospective analysis.
Lung Cancer. 2026;217:109450.
PubMed Abstract available

SHIRAISHI Y, Kishimoto J, Sugawara S, Mizutani H, et al
Final overall survival analysis of the APPLE study: atezolizumab and platinum-pemetrexed with or without bevacizumab for metastatic nonsquamous non-small cell lung cancer.
Lung Cancer. 2026;217:109447.
PubMed Abstract available

WEBER M, Raab AM, Schmitt KU, Busching G, et al
Insights from a randomized controlled trial on a digital lifestyle intervention in non-small cell lung cancer survivors following inpatient rehabilitation.
Lung Cancer. 2026;217:109433.
PubMed Abstract available

KANEDA H, Tachihara M, Toi Y, Kuyama S, et al
Phase II study of ramucirumab plus erlotinib for treatment-naive patients with EGFR-mutant non-squamous non-small cell lung cancer and pleural effusion (RELAY-Effusion).
Lung Cancer. 2026;217:109432.
PubMed Abstract available

Expression of concern for "'Recoverin as a paraneoplastic antigen in lung cancer: the occurrence of anti-recoverin autoantibodies in sera and recoverin in tumors' by Pavel P Philippov". [Lung Cancer 44(2) (2004) 193-198, https://doi.org/10.1016/j.lung
Lung Cancer. 2026;215:109332.
PubMed

WANG K, Ding Y, Wang Z, Zhao Y, et al
Risk stratification in stage I invasive non-mucinous lung adenocarcinoma based on high-risk histopathologic features.
Lung Cancer. 2026;215:109388.
PubMed Abstract available

VISBY L, Kehlet H, Secher EL, Moller-Sorensen H, et al
Outcomes of Video-Assisted Thoracoscopic Lobectomy in Octogenarians Following Enhanced Recovery After Surgery Protocols.
Lung Cancer. 2026;215:109384.
PubMed Abstract available

NAKAI T, Matsumoto Y, Yamada K, Watanabe T, et al
Novel thin convex-probe endobronchial ultrasound bronchoscope-guided cryobiopsy for a peripheral pulmonary lesion.
Lung Cancer. 2026;215:109375.
PubMed Abstract available

LAMBERTI G, Andrini E, Zappi A, Di Odoardo A, et al
Phase III meta-analysis of first-line chemo-immunotherapy in ES-SCLC: Survival benefit without detectable class-level differences.
Lung Cancer. 2026;215:109376.
PubMed Abstract available

DAVILA-DUPONT D, Arroyo-Hernandez M, Turcott JG, Palomares-Palomares CB, et al
Respiratory sarcopenia and prehabilitation in thoracic oncology: Diagnostic approaches and clinical implications.
Lung Cancer. 2026;215:108949.
PubMed Abstract available

ORTMEYER WELCH K, McGovern KA, Chen L, Welch JC, et al
SGLT2 inhibitor use reduces progression and surgical intervention of persistent pulmonary nodules.
Lung Cancer. 2026;215:109356.
PubMed Abstract available

ZHANG Y, Chen L, Dai W, Zhou Y, et al
Hypermethylation of SHOX2 and RASSF1A in intraoperative pleural lavage fluid as a molecular signature of aggressive tumor biology and high histologic grade in stage I lung adenocarcinoma.
Lung Cancer. 2026;215:109357.
PubMed Abstract available

LI Y, Zhang FX, Zhang WL, Shen MJ, et al
(18)F-FDG PET/CT and receptor-positive circulating tumor cells-based machine learning model for predicting poorly differentiated lung adenocarcinoma.
Lung Cancer. 2026;215:109353.
PubMed Abstract available

DONG X, Jian H, Huang M, Yuan S, et al
Osimertinib after definitive chemoradiotherapy in patients with unresectable stage III EGFR-mutated NSCLC: LAURA China cohort.
Lung Cancer. 2026;215:109343.
PubMed Abstract available

April 2026

LIANG J, Feng Y, Gui D, Zheng X, et al
A dynamic proteomic signature for the prediction of lung Cancer: a longitudinal analysis in the UK Biobank cohort.
Lung Cancer. 2026;217:109424.
PubMed Abstract available

IWAI C, Kimura Y, Matsui H, Fushimi K, et al
Protective effect of bevacizumab against interstitial lung disease in non-squamous non-small-cell lung cancer: a nationwide target trial emulation study.
Lung Cancer. 2026;217:109429.
PubMed Abstract available

ITO M, Ariyasu R, Fujishima S, Iso H, et al
Prognostic value of serum CYFRA21-1 in locally advanced non-small cell lung cancer undergoing durvalumab consolidation therapy after chemoradiotherapy.
Lung Cancer. 2026;217:109428.
PubMed Abstract available

SAIKI M, Inoue T, Takusagawa K, Homma K, et al
Association of tumor CD73 expression with clinical outcomes in small cell lung cancer treated with first-line chemo-immunotherapy.
Lung Cancer. 2026;216:109425.
PubMed Abstract available

ELTER T, Marschall U, Maier PM, Grellmann C, et al
Real-world evidence of the impact of guideline concordance on survival in non-small cell lung cancer.
Lung Cancer. 2026;216:109426.
PubMed Abstract available

GALLAGHER TJ, Kokot NC, Lopez J, Rodriguez E, et al
Association of cannabis use and lung cancer: a retrospective cohort study.
Lung Cancer. 2026;216:109421.
PubMed Abstract available

KUROSAKI T, Suzuki S, Watanabe Y, Kenmotsu H, et al
Immune-related gene expression profiling and alectinib efficacy for patients with ALK-Rearranged non-small cell lung cancer: exploratory analysis of a prospective observational study.
Lung Cancer. 2026;216:109416.
PubMed Abstract available

ZHAI W, Liang D, Yu X, Dai S, et al
Surgery after neoadjuvant immunochemotherapy versus immuno-chemoradiotherapy in patients with cN3 non-small cell lung cancer: A cohort study in two academic centers.
Lung Cancer. 2026;216:109409.
PubMed Abstract available

SOO RA, Fernandez-Penas P, Li M, Voon PJ, et al
Asia-Pacific practical consensus in the management of adverse events related to amivantamab-based therapies in non-small cell lung cancer.
Lung Cancer. 2026;216:109405.
PubMed Abstract available

KANDEMIR EA, Roeper J, Ansmann L, Hiltermann TJN, et al
Multidisciplinary tumor boards (MTBs) and survival Outcomes: Adherence to MTB recommendations in patients with lung cancer treated at two European cancer centers (AdThera-2).
Lung Cancer. 2026;216:109403.
PubMed Abstract available

YIU CH, Clarke SJ, Lu CY
Real-world outcomes of pembrolizumab-chemotherapy combination in metastatic non-small cell lung cancer by age and sex: A national population-based study.
Lung Cancer. 2026;214:109340.
PubMed Abstract available

CITARELLA F, Venanzi FM, Di Giovanni G, Takada K, et al
Family history enrichment in Non-Small cell Lung Cancer: A cross-sectional - prospective study to inform referral for germline testing.
Lung Cancer. 2026;214:109346.
PubMed Abstract available

GOUTAM S, Raghavan AA, Alday H, Meyers DE, et al
Outcomes and toxicities of immune checkpoint inhibitors in patients with lung cancer and pre-existing autoimmune disease.
Lung Cancer. 2026;214:109347.
PubMed Abstract available

TODA M, Takada K, Nomura K, Kosai K, et al
Lack of impact of antibiotics and proton pump inhibitors on the efficacy of preoperative chemoimmunotherapy in locally advanced non-small cell lung cancer: A multicenter retrospective study.
Lung Cancer. 2026;214:109344.
PubMed Abstract available

LI F, Qi L, Wusiman D, Chen J, et al
Comparative clinical utility of the 2024 Fleischner Society updated glossary versus traditional classifications for pulmonary subsolid nodules.
Lung Cancer. 2026;214:109306.
PubMed Abstract available

YIN LX, Huang ZJ, Wu L, Wang F, et al
Prognostic impact and treatment options for EGFR-mutant non-small cell lung cancer with concurrent EGFR amplification.
Lung Cancer. 2026;214:109339.
PubMed Abstract available

FERNANDEZ-BUSSY S, Yu Lee-Mateus A, Murillo-Torres RM, Gutierrez-Gallegos P, et al
Bronchoscopic pulsed-electric field ablation for carcinoid tumor: robotic-assisted and non-robotic approach.
Lung Cancer. 2026;214:109333.
PubMed Abstract available

ZHANG Q, Sun J, Yang Y, Xu B, et al
Survival analysis and prognostic factors in advanced NSCLC harboring EGFR PACC mutations: A multicenter retrospective study.
Lung Cancer. 2026;214:109341.
PubMed Abstract available

POMPILI C, Jaques L, Callister MEJ, Franks KN, et al
Patient-reported EORTC QLQ C-30 global health status decline predicts survival after video-assisted thoracoscopic (VATS) lung resection and stereotactic ablative radiotherapy (SABR): A 5 year follow-up from the Lilac study.
Lung Cancer. 2026;214:109335.
PubMed Abstract available

SUN Z, Liu T, Xu J, Wang B, et al
RET Fusion-Positive Lung Adenocarcinoma: Partner-Specific Clinicopathological Characteristics, Co-Mutation Profiles, and Implications for Targeted and Immunotherapy.
Lung Cancer. 2026;214:109314.
PubMed Abstract available

RECK M, Waller C, Sadjadian P, Kambartel K, et al
Feasibility and safety of nintedanib in combination with nivolumab in pretreated patients with advanced or metastatic adenocarcinoma of the lung - An AIO phase Ib/II trial.
Lung Cancer. 2026;214:109318.
PubMed Abstract available

HAYASHI H, Cho BC, Kim YJ, Lee SH, et al
Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis.
Lung Cancer. 2026;214:109305.
PubMed Abstract available

WANG J, Wang X, Li Y, Huang C, et al
Safety evaluation of tarlatamab: A pharmacovigilance study based on the FAERS database.
Lung Cancer. 2026;214:108801.
PubMed Abstract available

LI H, Chen Y, Wei L, Wu P, et al
HDAC1-modified lamin A/C drives nuclear deformation in RB1-deficient lung adenocarcinoma.
Lung Cancer. 2026;214:109301.
PubMed Abstract available

March 2026

COOPER AJ, Liang J, McDonald S, Arfe A, et al
Real-world multi-institution analysis of tarlatamab in patients with small cell lung cancer.
Lung Cancer. 2026;216:109390.
PubMed Abstract available

VICENTE-VALOR J, Aguado C, Mateos M, Tesolato S, et al
Microbiota biomarkers as predictors on immunotherapy response in patients with advanced non-small cell lung cancer.
Lung Cancer. 2026;216:109381.
PubMed Abstract available

LIN JT, Yang XN, Li XM, Zhang C, et al
Adjuvant immunotherapy may have no impact on survival in patients who received neoadjuvant immunotherapy for stage II-IIIB non-small cell lung cancer.
Lung Cancer. 2026;215:109389.
PubMed Abstract available

BARLESI F, Ahn JS, Solomon BJ, Nishio M, et al
Disease characteristics and treatment outcomes in patients with resected early-stage ALK-positive non-small cell lung cancer from the randomized ALINA trial.
Lung Cancer. 2026;216:109385.
PubMed Abstract available

KNAPP B, Waqar SN, Ward JP, Herzog BH, et al
Evaluating the safety and efficacy of chemotherapy in patients with relapsed small cell lung cancer combined with allopurinol and MycoPhenolate (CLAMP).
Lung Cancer. 2026;215:109382.
PubMed Abstract available

HUANG Y, Lin X, Li Z, Fang C, et al
Colony-stimulating factors improve neoadjuvant immunochemotherapy efficacy in non-small-cell lung cancer without EGFR or ALK mutations: A double-center real-world retrospective study.
Lung Cancer. 2026;215:109380.
PubMed Abstract available

LIN Z, Lyu Q, Li J, Fan L, et al
Molecular subtyping of small-cell lung cancer in clinical practice: Primary tumor-lymph node concordance, intratumoral heterogeneity, and genomic context in a Chinese cohort.
Lung Cancer. 2026;215:109377.
PubMed Abstract available

GOGA A, Soussi G, Mogenet A, Habert P, et al
Single-center retrospective cohort study of lung cancer associated with interstitial lung disease: Prognostic factors and molecular profile.
Lung Cancer. 2026;215:109379.
PubMed Abstract available

MARTIN LW, Wang X, Kozono D, Urbanic J, et al
CHIO3: CHemotherapy combined with immune checkpoint inhibitor for operable stage IIIA/B (N2) Non-Small cell lung cancer (AFT-46).
Lung Cancer. 2026;215:109374.
PubMed Abstract available

LV D, Zhu R, Wu G, Zhang Y, et al
Anlotinib + Toripalimab maintenance in Extensive-Stage small cell lung Cancer: Clinical efficacy and preclinical mechanism of anlotinib-induced neuroendocrine differentiation Suppression via Notch1.
Lung Cancer. 2026;215:109371.
PubMed Abstract available

ARAUJO BJ, Visani F, Paes RD, Negrete CL, et al
Increased detection of NRG1 fusions in non-squamous non-small cell lung cancer using combined DNA and RNA sequencing in a real-world cohort.
Lung Cancer. 2026;215:109370.
PubMed Abstract available

WANG J, Zhong Y, Chen B, Xu Y, et al
Immunotherapy rechallenge in Extensive-Stage small cell lung Cancer: A Real-World retrospective study.
Lung Cancer. 2026;215:109369.
PubMed Abstract available

ASMARA OD, Lancaster HL, Field JK, Davies MPA, et al
Volume and location of screen-detected lung nodules associated with lung cancer within two-year follow-up: Post hoc analysis from the UK Lung Cancer Screening (UKLS) trial.
Lung Cancer. 2026;215:109352.
PubMed Abstract available

AIBA T, Hara S, Tominaga S, Yamamoto R, et al
Real-world comparative effectiveness of atezolizumab versus durvalumab for extensive-stage small-cell lung cancer.
Lung Cancer. 2026;214:109355.
PubMed Abstract available

ILIE M, Heeke S, Rignol G, Pirlog R, et al
Genomic landscape of stage 0-IA lung adenocarcinoma identified by on-site reflex targeted NGS.
Lung Cancer. 2026;213:108943.
PubMed Abstract available

VASILIKI N, Vincent S, Zoe A, Michela S, et al
Prevention and management of amivantamab-induced dermatologic toxicities: a European expert consensus and practical algorithm.
Lung Cancer. 2026;213:108950.
PubMed Abstract available

BRASCIA D, Mangiameli G, Congedo MT, Mastromarino MG, et al
Immune-inflammatory predictors of early and brain recurrence in young patients with resected non-small cell lung cancer.
Lung Cancer. 2026;213:108946.
PubMed Abstract available

PAZ-ARES L, Veillon R, Majem M, Zhou C, et al
Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC.
Lung Cancer. 2026;213:108788.
PubMed Abstract available

ZHOU C, Tang KJ, Liu B, Kim SW, et al
Amivantamab plus chemotherapy versus chemotherapy for first-line treatment of participants with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer: PAPILLON Asia subgroup analysis.
Lung Cancer. 2026;213:109302.
PubMed Abstract available

HASHIMOTO K, Takahara M, Ishii R, Uno T, et al
Real-world occurrence of severe gastrointestinal bleeding in patients receiving amivantamab plus lazertinib: A two-case series among 25 consecutive cases.
Lung Cancer. 2026;213:108947.
PubMed Abstract available

CHENG Y, Huang JJ, Zhu HY, Shao D, et al
Prognostic value of baseline (18)F-FDG PET/CT metabolic parameters combined with clinical and pathological features in surgically resected ALK-positive non-small cell lung cancer.
Lung Cancer. 2026;213:108948.
PubMed Abstract available

SCHNEIDER JL, Muzikansky A, Krueger E, Gainor JF, et al
Combination therapy with lorlatinib and mitogen-activated protein kinase pathway inhibition in previously treated ALK- or ROS1-rearranged lung cancer.
Lung Cancer. 2026;213:108945.
PubMed Abstract available

HUANG WC, Kao TN, Liao SC, Lin MW, et al
Psychological features and quality of life in low-dose CT lung cancer screening: a comparative analysis with general population data.
Lung Cancer. 2026;213:109307.
PubMed Abstract available

NORDLING L, Backman M, Mezheyeuski A, Lindblad J, et al
Incremental prognostic value of immune cell densities beyond clinical parameters in non-small cell lung cancer.
Lung Cancer. 2026;213:108935.
PubMed Abstract available

AHN Y, Lee GD, Choi S, Kim HR, et al
Prognostic significance of consolidation-to-tumor ratio in stage IA solid predominant non-mucinous adenocarcinoma: a paradigm for risk stratification.
Lung Cancer. 2026;213:108934.
PubMed Abstract available

CAVAZZONI A, Pagano Mariano M, Palladini A, Digiacomo G, et al
Targeting HGF/MET and CXCL1/CXCR2 axes bypasses resistance to KRAS(G12C) inhibitors in NSCLC.
Lung Cancer. 2026;213:108939.
PubMed Abstract available

CHEN J, McNierney D, Zein JG, Vaszar LT, et al
Diagnostic performance of monarch robotic bronchoscopy with and without mobile cone-beam CT support.
Lung Cancer. 2026;213:108910.
PubMed Abstract available

LI M, Wang H, Zhang W, Lin D, et al
Combined intrathecal therapy via Ommaya reservoir and whole-brain radiotherapy improves survival in EGFR-mutant NSCLC patients with leptomeningeal metastases: a real-world cohort study.
Lung Cancer. 2026;213:108918.
PubMed Abstract available

GANG X, Sun Y, Hao J, Zhao S, et al
KRAS-mutant advanced NSCLC: efficacy and clinical outcomes from network meta-analysis and real-world evidence.
Lung Cancer. 2026;213:108930.
PubMed Abstract available

FEI X, Wu H, Li M, Yu J, et al
FAM83A promotes the progression of lung squamous cell carcinoma by inducing the epithelial-mesenchymal transition and inhibiting apoptosis via ERK pathway.
Lung Cancer. 2026;213:108917.
PubMed Abstract available

ABDEL-RAHMAN O, Taylor P, O'Brien M, Raskin J, et al
Nintedanib as switch maintenance treatment in malignant pleural mesothelioma (NEMO): A double-blind randomized phase II trial (EORTC-08112-LCG).
Lung Cancer. 2026;213:108906.
PubMed Abstract available

KIM DH, Kim M, Youk J, Kim TM, et al
Durvalumab-containing treatment for recurrent or metastatic pulmonary sarcomatoid carcinoma: A pooled post hoc analysis of two KCSG phase II trials.
Lung Cancer. 2026;213:108916.
PubMed Abstract available

February 2026

LIN SH, Kahangire DA, Nagar SP, Ahn MJ, et al
EGFR mutation status, treatment patterns, and outcomes in resectable early-stage non-small cell lung cancer prior to adjuvant EGFR-TKI approval: An international real-world study.
Lung Cancer. 2026;215:109348.
PubMed Abstract available

BROSSEAU S, Etienne H, Peoc'h K, Langlais A, et al
Club cell secretory protein (CCSP) serum concentration is a prognostic factor after surgical resection of localized non-small cell lung cancer in patients in the IFCT-0302 trial.
Lung Cancer. 2026;215:109345.
PubMed Abstract available

NICOS M, Stokowy T, Reszka K, Kowalczyk A, et al
Mutational landscapes of brain metastases across various histological subtypes of lung cancer.
Lung Cancer. 2026;214:109342.
PubMed Abstract available

KINEHARA Y, Matsumoto K, Shiroyama T, Komuta K, et al
Comparison of long-term survival between nivolumab plus ipilimumab with chemotherapy and pembrolizumab with chemotherapy in advanced non-small cell lung cancer: A multicenter retrospective cohort study.
Lung Cancer. 2026;214:109336.
PubMed Abstract available

STENSLAND EM, Stensgaard S, Eide IJZ, Nilssen Y, et al
Upfront treatment with osimertinib in lung cancer patients with and without active brain metastases, and the role of ctDNA as a biomarker; a phase II clinical trial (the FIOL study).
Lung Cancer. 2026;214:109338.
PubMed Abstract available

BARTOLOMEO V, Jongbloed M, Huijs JWJ, Filippi AR, et al
Patterns of progression in patients with synchronous oligometastatic non-small cell lung cancer after systemic and local radical treatment.
Lung Cancer. 2026;214:109337.
PubMed Abstract available

MAXFIELD N, Semprini J
Lung cancer incidence in counties at low and high risk of Radon Exposure: A Population-Based SEER analysis (1975-2022).
Lung Cancer. 2026;214:109334.
PubMed Abstract available

ROLIM I, Lopez-Beltran A, Pantarotto M, de Sousa E, et al
Altered bacteriome and mycobiome in small cell lung cancer: insights from microbial profiling.
Lung Cancer. 2026;214:109315.
PubMed Abstract available

NAIDOO J, Peters S, Runglodvatana Y, Li JY, et al
Domvanalimab combined with zimberelimab as first-line treatment in patients with PD-L1-high, advanced non-small cell lung cancer: Results from the randomized phase 2 ARC-10 study, Part1.
Lung Cancer. 2026;215:109316.
PubMed Abstract available

ALDER L, Mullikin TC, Lascola C, Sperduto PW, et al
Broadening clinical trial inclusivity of patients with lung cancer and brain metastases utilizing the Graded Prognostic Assessment (GPA): A call to action.
Lung Cancer. 2026;214:109317.
PubMed Abstract available

IACOVINO ML, Arenare L, Morabito A, Tiseo M, et al
Validity and responsiveness of patient-reported outcomes common terminology criteria for adverse events (PRO-CTCAE) among Italian lung cancer patients.
Lung Cancer. 2026;214:109312.
PubMed Abstract available

AKAGI K, Taniguchi H, Fukuda M, Yamazaki T, et al
Phase I study of amrubicin plus cisplatin and concurrent accelerated hyperfractionated thoracic radiotherapy for limited-stage small cell lung cancer.
Lung Cancer. 2026;214:109310.
PubMed Abstract available

WANG Y, Sun Z, Sridhar A, Ramalingam SS, et al
Participation in lung cancer biospecimen studies: an analysis of the ECOG-ACRIN phase 3 E1505 and E5508 clinical trials.
Lung Cancer. 2026;214:109304.
PubMed Abstract available

ZHONG CC, Yang Z, Chen M, Li Z, et al
Public perceptions of lung cancer screening: a population-based assessment of acceptability and feasibility.
Lung Cancer. 2026;214:109308.
PubMed Abstract available

HAYASAKA K, Shimokawa M, Haratake N, Notsuda H, et al
Survival outcomes of patients with uncommon EGFR mutations in surgically resected lung adenocarcinoma: A multi-institutional real-world database study (CReGYT-01 EGFR study).
Lung Cancer. 2026;212:108908.
PubMed Abstract available

ZWIJSEN K, Heirwegh E, Schillebeeckx E, Marcq E, et al
Multi-omic screening for pleural mesothelioma in Asbestos-Exposed Populations: A literature review and Recommendations.
Lung Cancer. 2026;212:108893.
PubMed Abstract available

CUNNIFFE C, Sperrin M, Walls G, Blackhall F, et al
External evaluation of the Manchester score in a contemporary SCLC cohort.
Lung Cancer. 2026;212:108884.
PubMed Abstract available

January 2026

BOWEN JONES S, Gurumurthy G, Hayton C, Lodhi A, et al
Corrigendum to "Radiotherapy outcomes in patients with interstitial lung disease and interstitial lung abnormalities: Adverse events and survival from a UK tertiary centre" [Lung Cancer 211 (2026) 108873.
Lung Cancer. 2026 Jan 29:108942. doi: 10.1016/j.lungcan.2026.108942.
PubMed

BARSOUK A, Heidlauf A, Goel K, Rushkin L, et al
Osimertinib dose-reduction and survival in 1L EGFR-mutated metastatic non-small cell lung cancer (mNSCLC).
Lung Cancer. 2026;213:108936.
PubMed Abstract available

GEORGE JE, George PS, Krishna JKM, Mathew A, et al
Corrigendum to "Global trends in lung cancer incidence and mortality by age, gender and morphology and forecast: A bootstrap-based analysis". [Lung Cancer 205 (2025) 108626].
Lung Cancer. 2026 Jan 11:108909. doi: 10.1016/j.lungcan.2026.108909.
PubMed

MARKS JA, Sweeney K, Elliott A, Gupta B, et al
SEZ6 expression and lineage plasticity in small cell lung cancer and transformed non-small cell lung cancer.
Lung Cancer. 2026;213:108913.
PubMed Abstract available

WANG Y, Zhang L, Zhan J, Wen L, et al
Comparative efficacy and safety of post-TKI treatments for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and network meta-analysis.
Lung Cancer. 2026;212:108914.
PubMed Abstract available

HUANG Y, Deng Q, Li J, Wang R, et al
Proteomic profiling of early-stage non-small cell lung cancer identifies a high-performance protein signature associated with postoperative recurrence.
Lung Cancer. 2026;213:108907.
PubMed Abstract available

SEYYEDSALEHI MS, Cani M, Wang Q, Thakur C, et al
Lung cancer in women: current evidence and future research priorities.
Lung Cancer. 2026;213:108905.
PubMed Abstract available

SUPIOT R, Gherardi A, du Manoir de Juaye L, Doghri O, et al
Cost-effectiveness of adjuvant alectinib in the treatment of patients with resected stage IB-IIIA ALK-positive non-small lung cancer in France, based on the ALINA study.
Lung Cancer. 2026;211:108885.
PubMed Abstract available

HERNANDEZ S, Conde E, Alonso M, Curto D, et al
Optimizing communication for ultrafast lung cancer biomarker testing: the UTOPIA pilot study.
Lung Cancer. 2026;211:108887.
PubMed Abstract available

LU KH, Xiao Y, Akhtar A, Tapia J, et al
Neighborhood matters: Predicting lung cancer screening adherence with explainable AI.
Lung Cancer. 2026;211:108882.
PubMed Abstract available

KIM DK, Chong Y, Yeo MK, Kang DH, et al
Multiomic analysis of treatment-naive NSCLC before the era of neoadjuvant immunotherapy reveals contrasting immune phenotypes in stage IIIA: node-dominant (T1N2) exhibiting hot versus tumor-dominant (T4N0) cold features.
Lung Cancer. 2026;211:108879.
PubMed Abstract available

LI G, Liu C, Xi P, Hou L, et al
Neoadjuvant immunotherapy plus chemotherapy in locally advanced stage III NSCLC patients undergoing definitive chemo-radiotherapy---a real?world multicenter retrospective study.
Lung Cancer. 2026;211:108883.
PubMed Abstract available

AMBROSINI P, Berghmans T, Occhipinti M, Durieux V, et al
Locoregional therapies in advanced and recurrent pleural mesothelioma: A systematic review.
Lung Cancer. 2026;211:108877.
PubMed Abstract available

WANG D, Mu S, Zhang M, Tao G, et al
A pathomics model for predicting response to chemo-immunotherapy in lung squamous cell carcinoma: A multicenter study.
Lung Cancer. 2026;211:108881.
PubMed Abstract available

MENDONCA L, Onwuka S, York S, Martinez-Gutierrez J, et al
Identifying eligible patients for the Australian national lung cancer screening program in primary care: A cross-sectional study using clinical decision support systems and evaluating PLCO(m2012) data quality.
Lung Cancer. 2026;211:108880.
PubMed Abstract available

FU L, Liu K, Liu Y, Gao Y, et al
Global patterns and trends in mesothelioma incidence: A retrospective cross-sectional study.
Lung Cancer. 2026;211:108878.
PubMed Abstract available

WU JY, Liang GZ, Chen TQ, Qiu HP, et al
Prognostic comparison of lymph node metastasis subtypes in lung adenocarcinoma: clinical implications of intranodal metastasis versus extranodal extension for optimizing R classification.
Lung Cancer. 2026;211:108876.
PubMed Abstract available

ZHANG B, Alder L, Rosner S, Desai A, et al
A multi-institutional perspective on tarlatamab administration and management of CRS/ICANS.
Lung Cancer. 2026;211:108870.
PubMed Abstract available

ALEXANDER M, Itchins M, Felthun J, Nagrial A, et al
Impact of PD-L1 on first-line osimertinib outcomes in EGFR-mutant NSCLC: real-world data from the AURORA25 study and meta-analysis.
Lung Cancer. 2026;211:108854.
PubMed Abstract available

TANG Y, Du W, Zhang X, Yang X, et al
Long-term survival with PD-1/PD-L1 inhibitors plus platinum-based chemotherapy versus chemotherapy alone in locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma: updated follow-up analysis.
Lung Cancer. 2026;211:108855.
PubMed Abstract available

BOWEN JONES S, Hayton C, Lodhi A, Umar A, et al
Radiotherapy outcomes in patients with interstitial lung disease and interstitial lung abnormalities: Adverse events and survival from a UK tertiary centre.
Lung Cancer. 2026;211:108873.
PubMed Abstract available

SINDI IA, Abu-Elsaoud AM, Almars AI, Ghouth NM, et al
KRAS(G12D/G13D)-USP15 axis promotes TGF-beta/SMAD signaling and glycolytic flux to accelerate NSCLC pathogenesis.
Lung Cancer. 2026;211:108848.
PubMed Abstract available

December 2025

JUNG HA, Lim J, Choi YL, Jeon YJ, et al
The role of APOBEC in early-stage epidermal growth factor receptor-mutant non-small cell lung cancer.
Lung Cancer. 2025;212:108892.
PubMed Abstract available

ZHOU DD, Lord SJ, Lin FP, Cooper WA, et al
Clinical impact of TP53 classifications in previously treated advanced driver-negative non-small cell lung cancer: A biomarker analysis of the OAK and POPLAR randomized clinical trials.
Lung Cancer. 2025;212:108891.
PubMed Abstract available

CHENG L, Wang D, Zhang X, Han B, et al
Inavolisib for PIK3CA-mutant non-small cell lung cancer: A case report.
Lung Cancer. 2025;212:108890.
PubMed Abstract available

JONGBLOED M, Damhuis RAM, Van Geffen WH, de Boer P, et al
Effect of treatment sequencing on outcome of patients with non-small cell lung cancer with a synchronous solitary extrathoracic metastasis.
Lung Cancer. 2025;212:108889.
PubMed Abstract available

YOON DW, Shin S, Kim CH, Jeon YJ, et al
Is sublobar resection a valid option for radiologically pure-solid clinical stage IA non-small cell lung cancer?: insights from real-world data and current status.
Lung Cancer. 2025;212:108886.
PubMed Abstract available

PHILLIPS WJ, Zhan LJ, Chowdhury D, Gill J, et al
Corrigendum to "Treatment and outcomes of limited stage small cell lung cancer in the Canadian small cell lung cancer database (CASCADE)" [Lung Cancer 210 (2025) 108840].
Lung Cancer. 2025 Dec 16:108875. doi: 10.1016/j.lungcan.2025.108875.
PubMed

PETERS BJM, Bohringer S, van Geffen E
Reply to letter to the editor "The effectiveness of pembrolizumab maintenance with or without pemetrexed after induction treatment for advanced non-squamous Non-Small-Cell lung cancer".
Lung Cancer. 2025;211:108872.
PubMed

DODD RH, Weber M, McFadden K, Rankin NM, et al
Informed choice for lung cancer screening: A randomised trial of three decision support tools.
Lung Cancer. 2025;211:108874.
PubMed Abstract available

SHAROVA E, Del Bianco P, Urso L, Silic-Benussi M, et al
Circulating microRNAs as biomarkers for risk assessment and prognostic stratification of pleural mesothelioma.
Lung Cancer. 2025;210:108852.
PubMed Abstract available

ISHIDA M, Yamada T, Tsunashima R, Morita M, et al
Prevalence and molecular landscape of NRG1 fusions in Japanese solid tumors: a nationwide data analysis using the C-CAT database.
Lung Cancer. 2025;210:108843.
PubMed Abstract available

HEIJBOER FWJ, Derks JL, van Nederveen FH, Hillen LM, et al
Treatment outcomes in patients with stage IV large cell neuroendocrine carcinoma: a nationwide registry study.
Lung Cancer. 2025;210:108830.
PubMed Abstract available

LUO YH, Yang CC, Wu SC, Su HW, et al
A novel agent, p-toluenesulfonamide, in the management of malignant pleural effusions.
Lung Cancer. 2025;210:108814.
PubMed Abstract available

WANG X, Shi W, Xiao Y, Wang H, et al
The immune desert tumor microenvironment in Thoracic SMARCA4-deficient undifferentiated tumors: spatial distribution characteristics and prognostic significance.
Lung Cancer. 2025;210:108817.
PubMed Abstract available

November 2025

LIU G, Abrahami D, Ramachandran P, Messina R, et al
Real-world incidence, prevalence, and clinical impact of brain metastases in patients with ALK-positive metastatic non-small cell lung cancer treated with first-line ALK tyrosine kinase inhibitors.
Lung Cancer. 2025;212:108858.
PubMed Abstract available

WU L, Li J, Xu CR, Biswas B, et al
Real-world use of and clinical outcomes with dacomitinib as first-line therapy in Asian patients with EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer: Final analysis of the ARIA study.
Lung Cancer. 2025;211:108856.
PubMed Abstract available

ANCEL J, Dewolf M, Nawrocki-Raby B, Durlach A, et al
AXL expression to predict resistance to immunotherapy in metastatic non-small cell lung cancer.
Lung Cancer. 2025;210:108853.
PubMed Abstract available

SHI D, Yan X, Liu J, Chen H, et al
CAR-T cell therapy for the treatment of lung cancer: Current challenges and emerging therapeutic strategies.
Lung Cancer. 2025;210:108849.
PubMed Abstract available

LU S, Fan Y, Dong X, Yu Y, et al
Entrectinib in Asian patients with ROS1 fusion-positive non-small cell lung cancer: updated efficacy and safety analysis.
Lung Cancer. 2025;211:108851.
PubMed Abstract available

LE H, Coulter J, Culver K, Cappelleri JC, et al
Patient and oncologist preferences for ALK+ advanced non-small cell lung cancer tyrosine kinase inhibitor treatments: a discrete choice experiment in the United States.
Lung Cancer. 2025;211:108850.
PubMed Abstract available

TORCHIA A, Sabatini A, Bengala E, Di Civita MA, et al
First-line treatment in EGFR-mutated non-small cell lung cancer: brief report of an individual patient data comparison of phase 3 clinical trials.
Lung Cancer. 2025;210:108845.
PubMed Abstract available

BATAH H, Zabor EC, Adcock B, Lee M, et al
Long-term outcomes of Extensive-Stage small cell lung cancer treated with chemotherapy or Chemo-immunotherapy: A propensity score adjusted cohort study.
Lung Cancer. 2025;210:108847.
PubMed Abstract available

STEWART DJ, Zhang B, Kurzrock R
Tarlatamab population survival kinetics in extensive-stage small cell lung cancer: brief report.
Lung Cancer. 2025;210:108844.
PubMed Abstract available

NICOS M, Galant N, Kowalczyk A, Peksa R, et al
Genetic composition and evolutionary trajectories of brain metastasis in non-small-cell lung cancer.
Lung Cancer. 2025;210:108842.
PubMed Abstract available

PHILLIPS WJ, Zhan LJ, Chowdhury D, Gill J, et al
Treatment and outcomes of limited stage small cell lung cancer in the Canadian small cell lung cancer database (CASCADE).
Lung Cancer. 2025;210:108840.
PubMed Abstract available

LUO B, Liang S, Zhong L, Gao W, et al
Impact of N1 lymph node burden on survival outcomes in non-skip pN2 non-small-cell lung cancer.
Lung Cancer. 2025;210:108839.
PubMed Abstract available

MA L, Zhang X, Xu S, Dai J, et al
NHWD-870 suppresses tumor proliferation via the BRD4/STRADA/CCND1 axis in small cell lung cancer.
Lung Cancer. 2025;210:108841.
PubMed Abstract available

ONDER AH
Letter to the Editor: On the clinical irrelevance of SUCRA rankings in relapsed small-cell lung cancer.
Lung Cancer. 2025;210:108837.
PubMed

PAN H, Yin H, Li W, Kong W, et al
Threshold of adequate resection margin for sub-lobar resection in peripheral clinical stage IA1-2 non-small cell lung cancer with tumor spread through air spaces.
Lung Cancer. 2025;210:108838.
PubMed Abstract available

KAKUTO S, Uchibori K, Yamamoto Y, Miyauchi E, et al
Tumor heterogeneity involving SCLC with a single exon deletion in RB1 and adenocarcinoma with EGFR-L718V mutation in EGFR-TKI-resistant lung cancer.
Lung Cancer. 2025;210:108833.
PubMed Abstract available

CAI H, Shu XO, Wu S, Gao YT, et al
Higher lung cancer risk among female never-smokers than males in a large married couple study.
Lung Cancer. 2025;210:108836.
PubMed Abstract available

CHEN X, Huan C, Yang P, He M, et al
Immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer patients with preexisting pulmonary emphysema or interstitial lung abnormalities.
Lung Cancer. 2025;210:108831.
PubMed Abstract available

SHOSHIHARA N, Matsumoto K, Shiroyama T, Komuta K, et al
Long-term survival comparison of first-line pembrolizumab versus pembrolizumab plus chemotherapy for patients with advanced non-small cell lung cancer: A multicenter propensity-matched cohort study.
Lung Cancer. 2025;210:108835.
PubMed Abstract available

KHORASANCHI A, Li M, Zhao S, Wei L, et al
Impact of immune-related and non-immune related hospital admissions on survival of patients with non-small cell lung cancer receiving first-line immunotherapy.
Lung Cancer. 2025;210:108832.
PubMed Abstract available

CHO BC, Charoentum C, Kim DW, Yang CT, et al
MAGELLAN arms B1 and B3: Durvalumab plus chemotherapy with and without oleclumab in treatment-naive metastatic non-small-cell lung cancer.
Lung Cancer. 2025;211:108834.
PubMed Abstract available

MURASE Y, Koba H, Kimura H, Matsumoto I, et al
Prognostic value of preoperative ctDNA and pathological venous invasion for recurrence in EGFR-mutated non-small cell lung cancer.
Lung Cancer. 2025;213:108818.
PubMed Abstract available

DESAI RK, Zhou EJ, Chan KKW
Systematic review and network meta-analysis: evaluation of systemic therapies for platinum refractory or resistant small cell lung cancer.
Lung Cancer. 2025;210:108812.
PubMed Abstract available

BORGHETTI P, D'Angelillo R, Facheris G, Borghesi A, et al
Recommendations for radiotherapy in patients with lung cancer and interstitial lung disease: A Delphi consensus process of the Italian association of radiotherapy and clinical oncology (AIRO).
Lung Cancer. 2025;210:108807.
PubMed Abstract available

BAILEY HR, Tam HZ, Vulkan D, Brunelli A, et al
Clinical characteristics and outcomes in participants with screen-detected clinical stage I lung cancer in the Yorkshire lung screening trial: A comparison of surgery versus stereotactic ablative radiotherapy.
Lung Cancer. 2025;210:108816.
PubMed Abstract available

FREHNER L, Schar S, Hayoz S, Petermichl V, et al
First-line immunotherapy +/- chemotherapy with or without upfront stereotactic radiotherapy (SRT) in patients with Non-Small cell lung cancer (NSCLC) with asymptomatic brain metastases.
Lung Cancer. 2025;210:108813.
PubMed Abstract available

TANNOURY E, Byrne SC, Hammer MM
Factors associated with lung cancer-specific mortality in lung cancer screening programs.
Lung Cancer. 2025;210:108815.
PubMed Abstract available

JIE GL, Zhong JX, Wang JZ, Cao ZQ, et al
Plasma proteomics profiling identifies predictive biomarkers for immunotherapy response in small-cell lung cancer.
Lung Cancer. 2025;210:108811.
PubMed Abstract available

CHEN ACC, Mok FST, Wong WKY, Lam BHW, et al
Pattern of failure, impact of local therapy, and characteristics of long-term responders with advanced EGFR mutation positive non-small cell lung cancer treated with first-line osimertinib.
Lung Cancer. 2025;210:108808.
PubMed Abstract available

UCHIBORI A, Okada S, Shimomura M, Furuya T, et al
Clinical impact of preoperative adipopenia on postoperative outcomes in non-small cell lung cancer surgery.
Lung Cancer. 2025;210:108810.
PubMed Abstract available

JUNG HA, Kim TM, Kim HR, Kim CG, et al
Phase II study of lazertinib and pemetrexed in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer with leptomeningeal metastases: the KCSG LU 21-01, LAZARUS study.
Lung Cancer. 2025;210:108809.
PubMed Abstract available

FAEHLING M, Fallscheer S, Schmiederer J, Strater J, et al
Pattern of brain metastases and survival in lung adenocarcinoma with KRAS or EFGR mutation.
Lung Cancer. 2025;209:108803.
PubMed Abstract available

GOMEZ-RANDULFE I, Monaca F, Cantale O, Reale ML, et al
Real-world outcomes of second-line carboplatin plus pemetrexed after first-line osimertinib in EGFR-mutant advanced NSCLC: An international multicentre cohort study.
Lung Cancer. 2025;209:108797.
PubMed Abstract available

WU X, Wan R, Wu L, Zhao M, et al
Safety and efficacy of YK-029A in previously treated EGFR T790M-Mutant NSCLC: A multi-center phase I trial.
Lung Cancer. 2025;209:108764.
PubMed Abstract available

MOK T, Nishio M, Yoshida T, Ahn MJ, et al
Efficacy and safety of brigatinib after alectinib in patients with ALK-positive NSCLC: Integrated analysis of the ALTA-2 and J-ALTA studies.
Lung Cancer. 2025;209:108793.
PubMed Abstract available

AGRAWAL P, Rotow J, Rocco G, Travis W, et al
Outcomes with neoadjuvant osimertinib and/or chemotherapy in patients with EGFR-mutant resectable non-small cell lung cancers.
Lung Cancer. 2025;209:108795.
PubMed Abstract available

CORTELLINI A, Garbo E, La Cava G, Citarella F, et al
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression >/= 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity.
Lung Cancer. 2025;209:108799.
PubMed Abstract available

GENUGTEN JHLTV, Faulkner D, Hahne JC, Poile C, et al
Discovery of actionable drug targets to enhance T-cell infiltration and immune checkpoint blockade efficacy in pleural mesothelioma.
Lung Cancer. 2025;209:108769.
PubMed Abstract available

VAN DER WEL JWT, Ernst SM, Jebbink M, van den Broek D, et al
Determining the optimal approach to identify osimertinib resistance; the first line osimertinib cohort of the OSIRIS study.
Lung Cancer. 2025;209:108783.
PubMed Abstract available

BORM FJ, Schelhaas MJ, Steeghs EMP, Timmer CW, et al
Liquid biopsy in BALF is now suitable for clinical practice in patients with suspected NSCLC.
Lung Cancer. 2025;209:108771.
PubMed Abstract available

LIU M, Townsend JP
KRAS G12C-associated immunotherapy benefit in NSCLC is substantially mediated by tobacco-induced tumor mutation burden, not allele-specific effects.
Lung Cancer. 2025;209:108749.
PubMed Abstract available

SCHEFFLER M, Tzala L, Louie K, Persigehl T, et al
Evaluating docetaxel effectiveness in KRAS G12C-mutated NSCLC: insights from a Real-World cohort.
Lung Cancer. 2025;209:108768.
PubMed Abstract available

October 2025

RICKETTS W, Sandsund C, Merchant Z, Franks K, et al
Delivering equitable access to prehabilitation services to optimise outcomes for patients with lung cancer - Best practice recommendations from a UK roundtable event.
Lung Cancer. 2025;210:108805.
PubMed Abstract available

HUIJS JWJ, Ogliari FR, Damhuis RAM, Jongbloed M, et al
Overall survival in patients with non-small cell lung cancer and leptomeningeal metastases: Data from the Dutch cancer Registry.
Lung Cancer. 2025;209:108806.
PubMed Abstract available

ISHIBASHI N, Nagata H, Yabe R, Ueda K, et al
Prognostic impact of pleural lavage cytology in EGFR-stratified resected non-small cell lung cancer.
Lung Cancer. 2025;209:108804.
PubMed Abstract available

ROLFO C, Gerber DE, Kotecha R, Ward JP, et al
The influence of body mass index on Tumor Treating Fields therapy in patients with metastatic non-small cell lung cancer: A post-hoc and simulation analysis from the phase III LUNAR study.
Lung Cancer. 2025;210:108802.
PubMed Abstract available

ABELE M, Karelin A, Pogoda M, Faust U, et al
Distinct genomic profile of pediatric lung carcinoma: High frequency of ALK fusions and TP53 mutations compared to adults.
Lung Cancer. 2025;209:108800.
PubMed Abstract available

VEERASATIAN T, Rattanapitoon SK, Thanchonnang C, Rattanapitoon NK, et al
Reframing BALF liquid biopsy: Defining the BALF-plasma continuum for molecular diagnosis and early lung cancer management.
Lung Cancer. 2025;209:108794.
PubMed

SEO J, Curran E, Whitty JA, Horn MK, et al
Patient preferences for EGFR mutation-targeted therapies in non-small cell lung cancer, with a focus on Exon 20 insertions.
Lung Cancer. 2025;209:108796.
PubMed Abstract available

BRANDAO M, Prisciandaro E, Xenophontos E, Mariolo A, et al
Definition of resectable stage III non-small cell lung cancer (NSCLC) for inclusion in clinical trials: A clinical case review by a pan-European multidisciplinary expert panel led by the EORTC Lung Cancer Group.
Lung Cancer. 2025;209:108798.
PubMed Abstract available

RODEN RT, Harmsen WS, Breen WG, Moffett JN, et al
Safety and outcomes of intensity modulated proton therapy in patients with non small cell lung cancer with interstitial lung disease.
Lung Cancer. 2025;209:108789.
PubMed Abstract available

TAKADA K, Shimokawa M, Cortellini A, Pinato DJ, et al
Probiotic supplement exposure and outcomes of patients with non-small cell lung cancer treated with first-line atezolizumab therapy: Pooled analysis of individual patient data from five randomized control trials.
Lung Cancer. 2025;209:108787.
PubMed Abstract available

REGUART N, Sampietro-Colom L, Juan-Vidal O, Aguilo M, et al
Corrigendum to "Characterization and economic burden of KRASG12C-mutant lung cancer in real-world Spanish practice: a retrospective observational study (SILK study)" [Lung Cancer 206 (2025) 108677].
Lung Cancer. 2025 Oct 8:108790. doi: 10.1016/j.lungcan.2025.108790.
PubMed

ANDREAS V, Faltys M, Alexander M, Rogers J, et al
Second-line treatment strategies and clinical outcomes after progression on chemoimmunotherapy in extensive-stage small-cell lung cancer.
Lung Cancer. 2025;209:108786.
PubMed Abstract available

CHENG WP, Lai CY, Lai HC, Liu JF, et al
Efficacy and safety of taxane versus gemcitabine for advanced stage lung squamous cell carcinoma in global EHR-based retrospective cohorts: A pairwise propensity score-matched comparison.
Lung Cancer. 2025;208:108751.
PubMed Abstract available

MELOSKY B, Chu QSC, Juergens RA, Snow S, et al
Canadian Perspectives Revisited: Consensus on the management of ALK-rearranged NSCLC.
Lung Cancer. 2025;208:108717.
PubMed Abstract available

SMESSEIM I, Pennycuick A, van Boerdonk RA, Janes SM, et al
Management of high-grade pre-invasive endobronchial lesions: To treat or not to treat?
Lung Cancer. 2025;208:108757.
PubMed Abstract available

LI R, Xie W, Chen R, Wu J, et al
The survival analysis of stage III and IV inoperable lung large cell neuroendocrine carcinoma and the role of LIPI in immunological stratification.
Lung Cancer. 2025;208:108698.
PubMed Abstract available

YU J, Shen X, Wen J, Chen T, et al
Prognostic impact and characteristics of ROS1 fusion in patients with surgically resected lung adenocarcinoma.
Lung Cancer. 2025;208:108743.
PubMed Abstract available

September 2025

LUNDGREN A, Leach S, Kaim J, Dutta N, et al
Coordinated humoral and cellular immune responses to COVID-19 vaccination in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Lung Cancer. 2025;209:108770.
PubMed Abstract available

PIERRET T, Greillier L, Guisier F, Daniel C, et al
Real-world efficacy and safety of amivantamab in EGFR exon-20-mutant non-small cell lung cancer in a French early-access program: Amexon 20 GFPC study.
Lung Cancer. 2025;209:108766.
PubMed Abstract available

MURATA D, Azuma K, Murotani K, Ito K, et al
Immune checkpoint inhibitor-induced interstitial lung disease with and without CTLA-4 regimen in non-small cell lung cancer patients and PD-L1 < 1 %: A multicenter, retrospective study.
Lung Cancer. 2025;209:108772.
PubMed Abstract available

ISLA D, Zugazagoitia J, Arriola E, Garcia-Campelo R, et al
Durvalumab plus platinum-etoposide in the first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): A single-arm clinical trial.
Lung Cancer. 2025;209:108763.
PubMed Abstract available

HAMADA S, Tomita Y, Fujino K, Miyashita A, et al
Association of lung silica deposition with epidermal growth factor receptor-mutant lung cancer.
Lung Cancer. 2025;209:108767.
PubMed Abstract available

REALE ML, Scattolin D, Vitale A, Passiglia F, et al
Advanced-stage ALK-positive non-small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database.
Lung Cancer. 2025;209:108762.
PubMed Abstract available

GUERRERA F, Gallina FT, Balzani E, Ambrosi F, et al
Attrition with adjuvant, neoadjuvant, and perioperative immunotherapy-based treatment protocols in patients with resectable non-small-cell lung cancer. A meta-analysis of prospective trials.
Lung Cancer. 2025;209:108760.
PubMed Abstract available

TAKEMURA C, Yoshida T, Yoshida Y, Inaba Higashiyama R, et al
Unveiling the molecular and clinical risk landscape of second primary lung cancer in resected non-small cell lung cancer.
Lung Cancer. 2025;208:108750.
PubMed Abstract available

SUGATA K, Aokage K, Taki T, Nomura K, et al
Impact of tumor cell burden beyond the elastic layer on prognosis in T2aN0M0 non-small cell lung cancer with visceral pleural invasion.
Lung Cancer. 2025;208:108759.
PubMed Abstract available

GURNEY J, Ongley D, Cameron L, Costello S, et al
Patterns of treatment prior to death among those with lung cancer: A national study in a universal healthcare context.
Lung Cancer. 2025;208:108761.
PubMed Abstract available

ZHANG C, Wang W, Bi N, Wang J, et al
Efficacy and safety of consolidative thoracic radiotherapy for Extensive-Stage Small-Cell lung cancer in the era of immunotherapy: A Real-World study.
Lung Cancer. 2025;208:108758.
PubMed Abstract available

WANG J, Cao H, He N, Liu X, et al
Evolving Trends in Surgically Managed Lung Cancer: A 16-Year Hospital-Based Epidemiological Analysis.
Lung Cancer. 2025;208:108754.
PubMed Abstract available

IWAMA E, Sakai K, Harada T, Kanda S, et al
Biological impact of chemotherapy during treatment with EGFR tyrosine kinase inhibitors for non-small cell lung cancer positive for EGFR activating mutations.
Lung Cancer. 2025;208:108756.
PubMed Abstract available

ZHANG R, Yan H, Tian F, Jiang Y, et al
Prognostic implications of uncommon EGFR exon 19 deletion-insertion mutations in non-small cell lung cancer treated with third-generation EGFR-TKIs.
Lung Cancer. 2025;208:108755.
PubMed Abstract available

WEBSTER L, Lawton S, Kipps E, Thackray K, et al
Durvalumab in locally advanced unresectable non-small cell lung cancer - Benchmarking real-world outcomes in England against published trial data.
Lung Cancer. 2025;209:108752.
PubMed Abstract available

AHN MJ, Lin SH, Yang CT, Lee JB, et al
Mutation testing, treatment patterns, and outcomes in patients with unresectable stage III EGFR-mutated non-small cell lung cancer treated with chemoradiotherapy: Final analysis of a global real-world study.
Lung Cancer. 2025;209:108748.
PubMed Abstract available

SUN F, Banwait MK, Singhal S, Herrmann A, et al
Clinical factors and molecular co-alterations impact outcomes in patients receiving first-line osimertinib for EGFR-mutated non-small cell lung cancer.
Lung Cancer. 2025;208:108747.
PubMed Abstract available

RAJARAM R, Huang Q, Johnson BH, Laxmanan B, et al
Implications of primary tumor size on overall survival in patients with multifocal T3 non-small cell lung cancer.
Lung Cancer. 2025;208:108746.
PubMed Abstract available

UTSUMI H, Yagishita S, Kawajiri K, Torasawa M, et al
Identification of poor prognostic factors using circulating extracellular vesicles in durvalumab consolidation therapy for locally advanced non-small cell lung cancer.
Lung Cancer. 2025;208:108732.
PubMed Abstract available

HUIJS JWJ, Sadowska AM, Degens JHRJ, Steendam CMJ, et al
Clinical risk factors for developing brain metastases during first-line (chemo-)immunotherapy in patients with non-small cell lung cancer without known baseline brain metastases.
Lung Cancer. 2025;208:108745.
PubMed Abstract available

CIAMMELLA P, Iori F, Borghetti P, Galaverni M, et al
Locally advanced NSCLC: overview of real-world pattern of recurrence in durvalumab era (LEOPARD trial).
Lung Cancer. 2025;207:108718.
PubMed Abstract available

JIANG Y, Lin Y, Mo L, Deng H, et al
Real-time non-invasive localization in sub-lobar resection for small pulmonary nodules: a noninferiority randomized clinical trial.
Lung Cancer. 2025;207:108724.
PubMed Abstract available

ONO S, Taniguchi H, Kuroda K, Hashimoto T, et al
Pemetrexed plus platinum as second-line treatment for patients with pleural mesothelioma treated with nivolumab plus ipilimumab.
Lung Cancer. 2025;207:108709.
PubMed Abstract available

TRUDU L, Rovesti G, Neri G, Pugliese G, et al
CAR-T for Lung Cancers: Challenges and Innovations.
Lung Cancer. 2025;207:108711.
PubMed Abstract available

ZHANG Y, Dai X, Liang J, Yang C, et al
Immunotherapy in EGFR-mutant NSCLC after TKI resistance: role of mutation subtypes and progression patterns.
Lung Cancer. 2025;207:108715.
PubMed Abstract available

ALAY A, Marin R, Aliagas E, Gausachs M, et al
Single-cell RNA-sequencing as a potential approach for studying intratumor heterogeneity in pleural mesothelioma.
Lung Cancer. 2025;207:108679.
PubMed Abstract available

SHAH R, Buchmeier EL, Kopp HG, Christoph DC, et al
First-line nivolumab plus ipilimumab in pleural mesothelioma: Efficacy and safety data from the real-world MesoNet study.
Lung Cancer. 2025;207:108702.
PubMed Abstract available

WANG R, Wei H, Qu C, Bai Y, et al
Unlocking the potential: tissue mutation abundance as a predictor for third-generation EGFR-TKI efficacy in NSCLC.
Lung Cancer. 2025;207:108699.
PubMed Abstract available

KALCHIEM-DEKEL O, Rakocevic R, Toumbacaris N, Tan KS, et al
Robotic-assisted bronchoscopy for histopathologic subtyping of primary lung adenocarcinoma.
Lung Cancer. 2025;207:108681.
PubMed Abstract available

PROVENCIO M, Cobo M, Rodriguez-Abreu D, Carcereny E, et al
Biomarker landscape in advanced NSCLC: insights from a national prospective registry.
Lung Cancer. 2025;207:108680.
PubMed Abstract available

August 2025

SHAO T, Yang J, Chen J, Zhang Y, et al
Retraction notice to "Antibody-drug conjugate components in association with the incidence of ADC-related interstitial lung disease: A systematic review and meta-analysis". [Lung Cancer 204 (2025) 108559].
Lung Cancer. 2025 Aug 31:108719. doi: 10.1016/j.lungcan.2025.108719.
PubMed

VILLALOBOS M, Ludwig JO, Konig M, Unsold L, et al
Communication about personal values of patients with advanced lung cancer in the hospital: results of a mixed-methods study.
Lung Cancer. 2025;208:108729.
PubMed Abstract available

SHIJUBOU N, Sumi T, Ishigooka T, Naraoka T, et al
Early pseudo-progression of brain metastases following tarlatamab therapy in relapsed small cell lung cancer.
Lung Cancer. 2025;207:108730.
PubMed

TAFUR A, Sebai A, Shi Z, Wei J, et al
Polygenic risk score to define risk of cancer-associated thrombosis among patients with lung cancer in a population-based study.
Lung Cancer. 2025;207:108712.
PubMed Abstract available

TATEISHI A, Horinouchi H, Kouno N, Takeda K, et al
Prediction recurrence in stage I epidermal growth factor receptor-mutated non-small cell lung cancer using multi-modal data.
Lung Cancer. 2025;207:108727.
PubMed Abstract available

PARK Y, Kang DH, Chung C
Integrating tumor macroenvironment, microenvironment and mechanobiology with organoid and organ-on-a-chip models for lung cancer immunotherapy.
Lung Cancer. 2025;207:108726.
PubMed Abstract available

SMEENK MM, van der Noort V, de Gooijer CJ, Theelen WSME, et al
Comment on "The effectiveness of pembrolizumab maintenance with or without pemetrexed after induction treatment for advanced non-squamous Non-Small-Cell lung cancer".
Lung Cancer. 2025;207:108725.
PubMed

KUROSAKI T, Kanemura H, Otani T, Kawanaka Y, et al
Impact of B7-H3 and DLL3 expression on the efficacy of PD-L1 blockade therapy in extensive-stage small cell lung cancer.
Lung Cancer. 2025;207:108723.
PubMed Abstract available

GUIJOSA A, Rios-Garcia E, Davila-Dupont D, Cruz-Rico G, et al
Stratifying risk in oligoprogressive EGFR-mutated non-small cell lung cancer (NSCLC): The role of liquid biopsy.
Lung Cancer. 2025;207:108722.
PubMed Abstract available

TU HY, Chen C, Chen C, Cheng C, et al
Chinese expert consensus on perioperative management of patients with resectable anaplastic lymphoma kinase-fusion non-small cell lung cancer.
Lung Cancer. 2025;208:108716.
PubMed Abstract available

GRAABAK G, Halvorsen TO, Gronberg BH, Killingberg KT, et al
Changes in use of radiotherapy for lung cancer - A Norwegian population-based study from 2000 until 2020.
Lung Cancer. 2025;207:108720.
PubMed Abstract available

MA W, Zhao B, Lang Y, Liu Z, et al
The 5-year survival outcomes analysis of EGFR-TKI or/and chemotherapy as initial adjuvant therapy for completely resected IIIA non-small cell lung cancer.
Lung Cancer. 2025;210:108721.
PubMed Abstract available

CHEN L, Zhang XH, Mao ZJ, Wang D, et al
Clinical outcomes and neuroendocrine features of transformed versus primary small-cell lung cancer.
Lung Cancer. 2025;207:108714.
PubMed Abstract available

YU Y, Pan Y, Zhou J, Mu S, et al
Dacomitinib in the treatment of EGFR-mutated non-small cell lung cancer with brain metastases: an open-label, multicenter, phase II study.
Lung Cancer. 2025;207:108710.
PubMed Abstract available

ALI AS, Irfan M
Second-hand smoke and survival in former smokers with lung cancer: time to act.
Lung Cancer. 2025 Aug 11:108713. doi: 10.1016/j.lungcan.2025.108713.
PubMed

NEYT M, Luyten J, Desimpel F, Camberlin C, et al
An economic evaluation of lung cancer screening with low-dose computed tomography in a high-risk population of (ex-)smokers in Belgium.
Lung Cancer. 2025;207:108697.
PubMed Abstract available

CUMMINGS AL, Sussell J, Rosettie KL, Moustaid FE, et al
A treatment-impact model of alectinib for the prediction of recurrence and associated costs in treating resectable ALK+ non-small cell lung cancer.
Lung Cancer. 2025;207:108701.
PubMed Abstract available

HUBERT J, Moldovanu D, van den Bosch I, de Nijs K, et al
Impact of recruitment method on informed decision-making in lung cancer screening in the 4-IN-THE-LUNG-RUN trial.
Lung Cancer. 2025;207:108686.
PubMed Abstract available

ZHANG Y, Zhao J, Ma Z, Yi J, et al
Immune checkpoint inhibitors for advanced non-small cell lung cancer with preexisting COPD and CT-defined emphysema: A systematic review and meta-analysis.
Lung Cancer. 2025;207:108700.
PubMed Abstract available

LIU G, Liu Y, Jing H, Chen T, et al
Global, regional, and national economic consequences of tracheal, bronchial, and lung cancer.
Lung Cancer. 2025;207:108685.
PubMed Abstract available

CHATURVEDI A, Som A
Transcriptome analysis reveals crucial oncogenic and tumor suppressor miRNAs in lung adenocarcinoma.
Lung Cancer. 2025;206:108540.
PubMed Abstract available

LEE J, Kim M, Han HJ, Kim S, et al
Real-world survival outcomes of immune checkpoint inhibitor therapy after standard treatment failure in EGFR-mutated NSCLC: A nationwide cohort study.
Lung Cancer. 2025;206:108682.
PubMed Abstract available

PRONSATI N, Liu G, Bauer TM, Felip E, et al
Managing lorlatinib together: An overview and practical guide for patients by ALK-positive NSCLC patients and medical experts.
Lung Cancer. 2025;206:108662.
PubMed Abstract available

FUJINO K, Suda K, Yoshikawa M, Shien K, et al
Adjuvant therapy in pStage IA1-IIA lung adenocarcinoma (pN0): A multicenter study focusing on EGFR mutations and recurrence patterns (CReGYT-01 EGFR study).
Lung Cancer. 2025;206:108672.
PubMed Abstract available

LU F, Lv C, Yang X, Zhuo M, et al
Icotinib plus chemotherapy as neoadjuvant treatment for resectable stage II-IIIB EGFR-mutant lung adenocarcinoma: a phase II study (NEOIPOWER).
Lung Cancer. 2025;206:108676.
PubMed Abstract available

NIEDERMAIER B, Rolf E, Allgauer M, Klotz LV, et al
Prognostic impact of lepidic growth in intermediate and high-grade lung adenocarcinoma.
Lung Cancer. 2025;206:108674.
PubMed Abstract available

LYNCH GA, Symonds J, Morley A, Azubuike-Dyer E, et al
Serum mesothelin as a response biomarker in pleural mesothelioma.
Lung Cancer. 2025;206:108670.
PubMed Abstract available

PANDEY A, Gomez E, Soto A, Jr MA, et al
A novel murine carcinogen-induced model recapitulates the progression and heterogeneity of human lung adenocarcinoma.
Lung Cancer. 2025;206:108581.
PubMed Abstract available

LANGER S, Medenwald D, Vordermark D, Schuette W, et al
Therapeutic modalities for superior sulcus tumor (Pancoast) tumor - A systematic review.
Lung Cancer. 2025;206:108640.
PubMed Abstract available

ZOLOV S, Chuikov S, Katkam SK, Chockley PJ, et al
Cell adhesion molecule-1 is a promising target for chimeric antigen receptors in lung adenocarcinoma.
Lung Cancer. 2025;206:108643.
PubMed Abstract available

MEDUSA PM, Carro N, Morgillo F, Guida GD, et al
Predictive role of functional respiratory tests in LUng toxicity in stage III NSCLC treated with chemo-, raDIO- and immuno-therapy: PRELUDIO TRIAL.
Lung Cancer. 2025;206:108617.
PubMed Abstract available

GAGNE A, Alessi JVM, Ricciuti B, Lamberti G, et al
Acquired SMARCA4 alterations: An uncommon contributor to cancer progression in lung adenocarcinomas.
Lung Cancer. 2025;206:108644.
PubMed Abstract available

DUMANE V, Runnels J, Flores R, Wolf A, et al
Long term side effects after volumetric modulated arc therapy to the pleura in patients with malignant pleural mesothelioma.
Lung Cancer. 2025;206:108639.
PubMed Abstract available

July 2025

GRONBERG M, Aanerud M, Halvorsen TO, Killingberg KT, et al
Associations between progastrin-releasing peptide (ProGRP) and neuron-specific enolase (NSE) and survival in patients with limited-stage small cell lung cancer (LS SCLC) receiving chemoradiotherapy (CRT).
Lung Cancer. 2025;207:108678.
PubMed Abstract available

ZENG L, Tong F, Xu X, Song L, et al
Comprehensive first-in-human phase I/II study of FHND-9041 in patients with EGFR-mutated advanced non-small cell lung cancer.
Lung Cancer. 2025;207:108684.
PubMed Abstract available

DINGEMANS AC, Syrigos K, Livi L, Paulus A, et al
Intracranial activity of sotorasib vs docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer from a global, phase 3, randomized controlled trial.
Lung Cancer. 2025;207:108683.
PubMed Abstract available

REGUART N, Sampietro-Colom L, Juan-Vidal O, Aguilo M, et al
Characterization and economic burden of KRASG12C-mutant lung cancer in real-world Spanish practice: a retrospective observational study (SILK study).
Lung Cancer. 2025;206:108677.
PubMed Abstract available

XENOPHONTOS E, Giaj Levra N, Durieux V, van Geffen WH, et al
Definition of resectable stage III non-small cell lung cancer: A systematic review from EORTC lung cancer group.
Lung Cancer. 2025;207:108671.
PubMed Abstract available

AHN Y, Kim SA, Lee SM, Ahn B, et al
Prognostic impact of extracapsular extension of lymph nodes in resected lung cancer: analysis by new N subcategories and histologic types.
Lung Cancer. 2025;206:108673.
PubMed Abstract available

ZHONG D, Sidorenkov G, Poelhekken K, Du Y, et al
Cost-effectiveness and budget impact of lung cancer screening in time of immunotherapy.
Lung Cancer. 2025;206:108669.
PubMed Abstract available

PAULUS A, Zemaitis M, Cicenas S, Zvirbule Z, et al
Safety, efficacy, and analysis of biomarkers in patients with advanced non-small cell lung cancer treated with the anti-IL1RAP antibody nadunolimab (CAN04) in combination with platinum doublet.
Lung Cancer. 2025;206:108664.
PubMed Abstract available

BOWEN JONES S, Price G, Faivre-Finn C
An introduction to pragmatic trials in lung cancer research: A multi-faceted approach.
Lung Cancer. 2025;206:108663.
PubMed Abstract available

NAIDU SB, Bhamani A, Murray C, Beyer K, et al
Corrigendum to "AGREE-II appraisal of lung cancer management clinical practice guidelines by the OPTIMA consortium". [Lung Cancer 205 (2025) 108610].
Lung Cancer. 2025 Jul 8:108659. doi: 10.1016/j.lungcan.2025.108659.
PubMed

FROST MG, Jensen KJ, Jimenez-Solem E, Qvortrup C, et al
Corrigendum to "Sex disparities in advanced non-small cell lung cancer survival: A Danish nationwide study" [Lung Cancer 202 (2025) 108485].
Lung Cancer. 2025 Jul 8:108658. doi: 10.1016/j.lungcan.2025.108658.
PubMed

NYKAZA I, An A, Villena-Vargas J, Mount L, et al
Disparities in adherence to guideline-concordant care and receipt of immunotherapy for Non-Small cell lung cancer in the United States.
Lung Cancer. 2025;206:108661.
PubMed Abstract available

CHENG Y, Huang GJ, Chen XB, Zhu HY, et al
Value of (18)F-FDG PET metabolic parameters combined with the dynamic monitoring of molecular residual disease (MRD) in predicting the prognosis of non-small-cell lung cancer after surgery.
Lung Cancer. 2025;206:108660.
PubMed Abstract available

COOLEY ME, Kim SS, Xiong N, Heiling H, et al
Clearing the air: Empowering high-risk adults with digital tools for smoking cessation and lung cancer screening adoption.
Lung Cancer. 2025;206:108647.
PubMed Abstract available

ISO H, Ariyasu R, Fujishima S, Ito M, et al
Prognostic impact of HNF4alpha expression in TTF-1-negative non-squamous NSCLC treated with immune checkpoint inhibitor.
Lung Cancer. 2025;205:108631.
PubMed Abstract available

NAKAI T, Tanaka S, Nagamine H, Miyamoto A, et al
Application of endobronchial ultrasound-guided cryobiopsy for centrally located intrapulmonary lesions: A retrospective cohort study.
Lung Cancer. 2025;205:108636.
PubMed Abstract available

YAN B, Zhang B, Chu T, Zhang W, et al
Osimertinib combined with anlotinib as first-line treatment in advanced or metastatic NSCLC patients with EGFR mutation: a prospective, single arm, exploratory study.
Lung Cancer. 2025;205:108627.
PubMed Abstract available

XIE Y, Yang L, Fang H, Yu C, et al
Genomic profiling and prognostic factors of leptomeningeal metastasis in EGFR-mutant NSCLC after resistant to third-generation EGFR-tyrosine kinase inhibitors.
Lung Cancer. 2025;205:108593.
PubMed Abstract available

ZHANG X, Nie Z, van Tuinen M, van de Wauwer C, et al
Effectiveness and safety of different wire types for preoperative localization of pulmonary nodules: A systematic review and meta-analysis.
Lung Cancer. 2025;205:108620.
PubMed Abstract available

NAVANI N, Sharman A, Evison M, Shepherd P, et al
Achieving equitable, timely and comprehensive biomarker testing for patients with NSCLC.
Lung Cancer. 2025;205:108618.
PubMed Abstract available

LI JJ, Zhen X, Liu L, Yan X, et al
Targeting IDH2 promotes antitumor immunity through epigenetic activation of cGAS-STING pathway.
Lung Cancer. 2025;205:108611.
PubMed Abstract available

KIM JY, Lee GD, Choi S, Kim HR, et al
Revisiting margin adequacy in sublobar resection for pure ground-glass opacity adenocarcinomas.
Lung Cancer. 2025;205:108595.
PubMed Abstract available

SUZUKI M, Shinozaki-Ushiku A, Yuhara S, Nagano M, et al
The prognostic impact of extra-alveolar invasion in lung adenocarcinoma.
Lung Cancer. 2025;205:108612.
PubMed Abstract available

CHENG S, Zhang R, Yang F, Li J, et al
Induction therapy with dabrafenib, trametinib, and PD-1 inhibitor and surgical conversion in unresectable stage III non-small cell lung cancers with BRAF V600E mutation: 2 cases.
Lung Cancer. 2025;205:108592.
PubMed Abstract available

ABOLFATHI H, Kordahi M, Armero VS, Gagne A, et al
Clinicopathologic characteristics, co-mutation landscape, and survival outcomes of KRAS-G12D mutant lung adenocarcinoma in comparison to KRAS-G12C and EGFR-mutated subtypes.
Lung Cancer. 2025;205:108596.
PubMed Abstract available

June 2025

TACHIHARA M, Shoda H, Akazawa Y, Ota T, et al
Durvalumab plus irinotecan + cisplatin for untreated extensive-stage small cell lung cancer: REBORN, phase II study (WJOG13520L).
Lung Cancer. 2025;206:108637.
PubMed Abstract available

WANG H, Wang L, Gao N, Li H, et al
Advances in the treatment of brain metastases in EGFR-mutant non-small cell lung cancer.
Lung Cancer. 2025;206:108641.
PubMed Abstract available

FERNANDEZ-BUSSY S, Funes-Ferrada R, Yu Lee-Mateus A, Vaca-Cartagena BF, et al
Transforming lung cancer diagnosis: the role of robotic-assisted bronchoscopy in early detection and staging.
Lung Cancer. 2025;206:108646.
PubMed Abstract available

PETERS BJ, van Geffen E, Hilarius D, Bohringer S, et al
The effectiveness of pembrolizumab maintenance with or without pemetrexed after induction treatment for advanced non-squamous Non-Small-Cell Lung cancer.
Lung Cancer. 2025;206:108642.
PubMed Abstract available

SHI Y, Chen R, Xiong Y, Geng R, et al
MRD status combined with TNM staging optimizes postoperative prognostic stratification in non-small cell lung cancer: a meta-analysis and systematic review.
Lung Cancer. 2025;206:108634.
PubMed Abstract available

QIAO K, Zhou T, Dong Y, Liu N, et al
Relationship between clinicopathological characteristics and PET/CT uptake in lung cancer: [(18)F]FAPI versus [(18)F]FDG.
Lung Cancer. 2025;206:108645.
PubMed Abstract available

OLLILA H, Tidjani A, Park BJ, Jones DR, et al
Nonagenarians: Outcomes after lung cancer surgery.
Lung Cancer. 2025;206:108632.
PubMed Abstract available

ZENKE Y, Niho S, Toi Y, Yamaguchi M, et al
Phase III study of ramucirumab plus docetaxel versus atezolizumab for previously treated PD-L1 low or negative advanced non-small-cell lung cancer: WJOG10317L study.
Lung Cancer. 2025;206:108633.
PubMed Abstract available

MOGHANAKI D, Cameron EA, Garon EB
Unbridled Enthusiasm for Neoadjuvant Chemoimmunotherapy followed by Surgery for Locally Advanced Non-Small Cell Lung Cancer.
Lung Cancer. 2025 Jun 20:108628. doi: 10.1016/j.lungcan.2025.108628.
PubMed

ZHANG M, Tang Y, Liang J, Zhu L, et al
Combination of anlotinib and irinotecan as second-line therapy in extensive-stage small-cell lung cancer relapsed within six months: a single-arm phase ? study.
Lung Cancer. 2025;205:108630.
PubMed Abstract available

GAWLI CS, Patil BR, Nagpure NR, Patil CR, et al
Prevalence of osimertinib-induced cardiotoxicity in non-small cell lung cancer patients: a systematic review and meta-analysis.
Lung Cancer. 2025;205:108629.
PubMed Abstract available

SUNG H, Jiang C, Schafer EJ, Bandi P, et al
Burden and trends in subsequent primary lung cancer incidence by sex in the United States.
Lung Cancer. 2025;205:108625.
PubMed Abstract available

GEORGE JE, George PS, Krishna JKM, Mathew A, et al
Global trends in lung cancer incidence and mortality by age, gender and morphology and forecast: A bootstrap-based analysis.
Lung Cancer. 2025;205:108626.
PubMed Abstract available

CROUCH SAW, Peindl M, Bencurova E, Caliskan A, et al
Transcriptome and protein network analyses of 3D-tissue lung cancer models reveal combinatorial targets for KRAS(G12C)-mutation.
Lung Cancer. 2025;206:108624.
PubMed Abstract available

PEREZ-PEREZ M, de Sola-Llamas CG, Macias-Garcia L
Diagnostic accuracy of the Idylla mutation test for detecting EGFR mutations in non-small cell lung cancer: a meta-analysis.
Lung Cancer. 2025;205:108623.
PubMed Abstract available

GEMELLI M, Cortinovis D, Carola G, Moretti L, et al
Efficacy of immune checkpoint inhibitors (ICIs) in PD-L1 negative Non-Small Cell Lung Cancer (NSCLC) - A meta-analysis based on reconstructed individual participant data.
Lung Cancer. 2025;205:108621.
PubMed Abstract available

SRIDHAR A, Adjei A, Montori VM, Leventakos K, et al
Shared decision making for personalized lung cancer care.
Lung Cancer. 2025 Jun 9:108614. doi: 10.1016/j.lungcan.2025.108614.
PubMed

WU Y, Xie Y, Chen Y, Li J, et al
Bronchial washing fluid supernatant serves as a novel liquid biopsy specimen for genome profiling in advanced non-small cell lung cancer.
Lung Cancer. 2025;205:108622.
PubMed Abstract available

GUDINA AT, Fitzgibbon ML, Peterson CE, Byrne C, et al
Geographic disparities in lung cancer screening uptake in the United States using the 2021 United States Preventive Services Task Force Guidelines.
Lung Cancer. 2025;205:108615.
PubMed Abstract available

ZHANG Q, Yang Y, Xie M, Zhou Z, et al
Survival and prognostic factors of HER2-mutant advanced non-small cell lung cancer with brain metastases.
Lung Cancer. 2025;205:108616.
PubMed Abstract available

NAIDU SB, Bhamani A, Murray C, Beyer K, et al
AGREE-II appraisal of lung cancer management clinical practice guidelines by the OPTIMA consortium.
Lung Cancer. 2025;205:108610.
PubMed Abstract available

KRAYIM B, Shalata W, Bar J, Moskovitz M, et al
Lurbinectedin for extensive stage - small cell lung cancer (ES-SCLC): real world response patterns and survival outcomes.
Lung Cancer. 2025;205:108598.
PubMed Abstract available

THUNNISSEN E, Blaauwgeers H, Filipello F, Lissenberg-Witte B, et al
Corrigendum to "A reproducibility study on invasion in small pulmonary adenocarcinoma according to the WHO and a modified classification, supported by biomarkers" [Lung Cancer 199 (2025) 108060].
Lung Cancer. 2025;204:108488.
PubMed

MA Z, Zhang Y
A Reply to comment on "Long-term outcomes of neoadjuvant gefitinib in resectable stage II-IIIA non-small cell lung cancer: A phase II, prospective cohort study".
Lung Cancer. 2025;204:108537.
PubMed

ONDER AH
Delayed central nervous system progression with atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer (LU23-15).
Lung Cancer. 2025;204:108536.
PubMed

ZHANG B, Zhang J
Comment on "Long-term outcomes of neoadjuvant gefitinib in resectable stage II-IIIA non-small cell lung cancer: A phase II, prospective cohort study".
Lung Cancer. 2025;204:108515.
PubMed

AHMAD WKM, Bedau T, Wang Y, Michels S, et al
Development and clinical validation of a prognostic algorithm for stroma-tumor ratio quantification in non-small cell lung cancer.
Lung Cancer. 2025;205:108613.
PubMed Abstract available

DI LECCE C, Eccher S, Simbolo M, Cocomazzi A, et al
ARID1A mutational status in non-small cell lung cancer: from molecular pathology to clinical implications with a focus on the relationships with EGFR.
Lung Cancer. 2025;205:108594.
PubMed Abstract available

OKADA A, Sakata Y, Oya Y, Sakata S, et al
Investigation of cardiotoxicity in patients treated with osimertinib: findings from the OSI-FACT study.
Lung Cancer. 2025;204:108589.
PubMed Abstract available

TANAKA S, Nozaki K, Watanabe S, Yanagimura N, et al
Risk of lung injury with immune checkpoint inhibitors after talc pleurodesis: A retrospective study.
Lung Cancer. 2025;204:108590.
PubMed Abstract available

RUAN Z, Zeng L, Zhang J, Qin H, et al
Intrathecal nivolumab and IL-2 for treatment of leptomeningeal metastases in EGFR-mutated lung adenocarcinoma.
Lung Cancer. 2025;204:108586.
PubMed Abstract available

CHEN T, Liu F
Neoadjuvant immunotherapy in early-stage NSCLC: navigating biomarker dilemmas and special population challenges.
Lung Cancer. 2025;204:108588.
PubMed Abstract available

ROMA L, Chijioke O, Flury DV, Kocher GJ, et al
Unusual relapse dynamics in EGFR-mutated lung adenocarcinoma uncovered by genomic profiling: Insights from a case report.
Lung Cancer. 2025;204:108587.
PubMed Abstract available

WHEATLEY-PRICE P, Navani V, Pabani A, Routy B, et al
Real-world survival outcomes, treatment patterns, and impact of PD-L1 expression among patients with unresectable, stage III NSCLC treated with CRT --> durvalumab in Canada: The RELEVANCE study.
Lung Cancer. 2025;204:108583.
PubMed Abstract available

FACCHINETTI F, Camerini A, Bennati C, Bordi P, et al
A prospective study on clinicians' attitudes and survival outcomes for patients with advanced NSCLC and poor performance status in the immunotherapy era: PICASO (GOIRC-04-2020).
Lung Cancer. 2025;204:108580.
PubMed Abstract available

EKLUND EA, Orgard M, Wallin D, Sayin SI, et al
Equalizing prognostic disparities in KRAS-mutated stage III NSCLC patients: addition of durvalumab to combined chemoradiotherapy improves survival.
Lung Cancer. 2025;204:108573.
PubMed Abstract available

YAMADA J, Hazama D, Fukui T, Yatani A, et al
Midazolam with fentanyl for endobronchial ultrasound-guided transbronchial needle aspiration: a randomized, double-blind, phase III study.
Lung Cancer. 2025;204:108556.
PubMed Abstract available

SHAO T, Yang J, Chen J, Zhang Y, et al
Antibody-drug conjugate components in association with the incidence of ADC-related interstitial lung disease: A systematic review and meta-analysis.
Lung Cancer. 2025;204:108559.
PubMed Abstract available

SUGAI M, Amino Y, Fujishima S, Nibuya K, et al
Impact of immune-related adverse event severity on overall survival in patients with advanced NSCLC receiving immune checkpoint inhibitors therapy, with a focus on combination regimens.
Lung Cancer. 2025;204:108555.
PubMed Abstract available

MURAT-ONANA ML, Ramalingam SS, Janne PA, Gray JE, et al
EGFR mutation testing across the osimertinib clinical program.
Lung Cancer. 2025;204:108549.
PubMed Abstract available

KIM D, Lee J, Jung M, Yim K, et al
Whole slide image-level classification of malignant effusion cytology using clustering-constrained attention multiple instance learning.
Lung Cancer. 2025;204:108552.
PubMed Abstract available

GUCKENBERGER M, Opitz I, Dellaporta T, Curioni-Fontecedro A, et al
Multimodality treatment in synchronous oligometastatic NSCLC: Analysis of the ETOP CHESS trial.
Lung Cancer. 2025;204:108553.
PubMed Abstract available

SERNA-BLASCO R, Mediavilla-Medel P, Medina K, Sala MA, et al
Comprehensive molecular profiling of advanced NSCLC using NGS: Prevalence of druggable mutations and clinical trial opportunities in the ATLAS study.
Lung Cancer. 2025;204:108550.
PubMed Abstract available

May 2025

FUJISAKI T, Miyauchi E, Kida G, Miura Y, et al
Durvalumab after concurrent chemoradiotherapy for sensitizing epidermal growth factor receptor-mutant stage III non-small cell lung cancer: A Japanese Real-World data analysis.
Lung Cancer. 2025;205:108597.
PubMed Abstract available

MATSUBARA T, Shimokawa M, Wakasu S, Haro A, et al
Controlling nutritional status predicts postoperative survival and acute exacerbation in resected non-small cell lung cancer with interstitial lung disease.
Lung Cancer. 2025;205:108591.
PubMed Abstract available

NOMURA S, Sekino Y, Shiraishi Y, Toi Y, et al
A treatment-related death predictive score for treatment-naive advanced non-small cell lung cancer.
Lung Cancer. 2025;204:108584.
PubMed Abstract available

MOORE WH, Silk M, Bhattacharji P, Pua BB, et al
Early experience with PEF in the setting of recalcitrant stage IV lung cancer.
Lung Cancer. 2025;204:108575.
PubMed Abstract available

LEIGHL NB, Trigo J, Park K, Lee SH, et al
Intracranial and systemic progression on amivantamab in platinum-treated epidermal growth factor receptor exon 20 insertion-mutated advanced non-small cell lung cancer.
Lung Cancer. 2025;205:108579.
PubMed Abstract available

KAKIUCHI Y, Saruwatari K, Tokito T, Iriki T, et al
Impact of durvalumab re-administration after moderate symptomatic pneumonitis in locally advanced non-small cell lung cancer.
Lung Cancer. 2025;204:108578.
PubMed Abstract available

GOURLAY E, Banfill K, Merchant Z, Goodley P, et al
Feasibility, acceptability and clinical outcomes of a real-world, regional lung cancer prehabilitation programme for patients undergoing curative intent radiotherapy.
Lung Cancer. 2025;204:108572.
PubMed Abstract available

NGUYEN MH, Le MHN, Bui AT, Le NQK, et al
Artificial intelligence in predicting EGFR mutations from whole slide images in lung Cancer: A systematic review and Meta-Analysis.
Lung Cancer. 2025;204:108577.
PubMed Abstract available

YANG G, Yoon HI, Lim SM, Hong MH, et al
Association of thyroid radiation dose with thyroid dysfunction in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy followed by maintenance immunotherapy.
Lung Cancer. 2025;204:108574.
PubMed Abstract available

CRESPI V, Delcuratolo MD, Minuti G, Montrone M, et al
Real-world outcomes of subsequent treatment strategies after durvalumab consolidation in stage III unresectable non-small cell lung cancer.
Lung Cancer. 2025;204:108576.
PubMed Abstract available

WU K, Bi K, Shen M, Tang C, et al
Decision-making tree model for distinguishing between benign and malignant subpleural pulmonary lesions based on ultrasonic strain elastography.
Lung Cancer. 2025;203:108547.
PubMed Abstract available

QIN Y, Mo Y, Li P, Liang X, et al
Concurrent immunotherapy improves progression-free survival but increases toxicity in unresectable stage III NSCLC.
Lung Cancer. 2025;203:108544.
PubMed Abstract available

NADAL E, Martin-Martorell P, Benitez JC, Sala MA, et al
Efficacy and safety of bintrafusp alfa evaluated in a phase II single-arm clinical trial in previously treated advanced pleural mesothelioma.
Lung Cancer. 2025;203:108545.
PubMed Abstract available

JIN W, Ding Z, Zhang M, Shen L, et al
The global burden of mesothelioma and its association with asbestos bans, 1990-2021: a population-based study.
Lung Cancer. 2025;203:108534.
PubMed Abstract available

BOSSE Y, Boudreau DK, Saavedra Armero V, Li Z, et al
Frequency of targetable genetic alterations in resectable lung adenocarcinoma: Results from the LORD project.
Lung Cancer. 2025;203:108530.
PubMed Abstract available

LIN YD, Li HJ, Hong HZ, Qi YF, et al
Genomic profiling of aggressive pathologic features in lung adenocarcinoma.
Lung Cancer. 2025;203:108460.
PubMed Abstract available

April 2025

LINTAS C, Petti R, Colella G, Cassano I, et al
Beyond environmental risk: Genetic insights into lung cancer susceptibility through whole exome analysis.
Lung Cancer. 2025;204:108560.
PubMed Abstract available

SHIRAI Y, Shukuya T, Asao T, Takahashi K, et al
Epidemiology and clinical course of large cell neuroendocrine carcinoma of the lung: The Japanese lung cancer registry study.
Lung Cancer. 2025;204:108557.
PubMed Abstract available

CHOUAID C, Bosquet L, Knott C, Li Z, et al
Real-world frontline treatments in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor exon 20 insertions and adjusted comparisons versus amivantamab plus chemotherapy from the PAPILLON study.
Lung Cancer. 2025;203:108548.
PubMed Abstract available

BARSOUK A, Elghawy O, Watts A, Reed-Guy L, et al
Osimertinib vs. Afatinib in 1L therapy of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC): A multi-institution, real-world survival analysis.
Lung Cancer. 2025;203:108551.
PubMed Abstract available

SHIRAISHI Y, Shimose T, Tobino K, Toi Y, et al
Atezolizumab with carboplatin plus nab-paclitaxel combination therapy for advanced nonsquamous non-small cell lung cancer with impaired renal function: A multicenter, single-arm phase 2 trial (RESTART, LOGiK 2002).
Lung Cancer. 2025;203:108543.
PubMed Abstract available

LEE JH, Cha S, Ko EJ, Kim W, et al
Clinical effect of pulmonary rehabilitation during radiotherapy in lung cancer: A randomized controlled trial.
Lung Cancer. 2025;204:108546.
PubMed Abstract available

VAES RDW, Cortiula F, Lyu S, Hiltermann TJN, et al
Chemoradiotherapy efficacy in patients with stage III non-small cell lung cancer (NSCLC): A prognostic clinical and biomarker-based model.
Lung Cancer. 2025;203:108541.
PubMed Abstract available

DHAEYER S, Missault E, Surmont V, Vermaelen K, et al
Outcome of temozolomide in relapsed small cell lung cancer: A retrospective single center analysis.
Lung Cancer. 2025;203:108539.
PubMed Abstract available

PAN Y, Gu Q
Efficacy and safety of targeted therapy combined with anti-angiogenesis treatment in brain metastases of non-small cell lung cancer: a systematic review and meta-analysis.
Lung Cancer. 2025;203:108532.
PubMed Abstract available

SARKAR S, Choa E, Manzo LL, Richman I, et al
Predictors and Uptake of Lung Cancer Screening in the US: An Integrative Literature Review.
Lung Cancer. 2025;203:108529.
PubMed Abstract available

WU Q, Li Q, Qin Y
A cost-effectiveness analysis of amivantamab plus lazertinib versus osimertinib in the treatment of US and Chinese patients with EGFR-mutated advanced non-small cell lung cancer.
Lung Cancer. 2025;203:108533.
PubMed Abstract available

AVANCINI A, Giaj-Levra N, Minuti G, Pasqualini G, et al
Current diagnostic and therapeutical approaches to bone metastases in patients with non-small cell lung cancer: A cross-sectional study.
Lung Cancer. 2025;203:108531.
PubMed Abstract available

ROSENLUND L, Guldbrandsen K, Ahlborn LB, Bloch M, et al
ctDNA can detect minimal residual disease in curative treated non-small cell lung cancer patients using a tumor agnostic approach.
Lung Cancer. 2025;203:108528.
PubMed Abstract available

AN Z, Ning Y, Mei J, Yang C, et al
Evaluating the prognostic impact of EGFR mutation on adjuvant chemotherapy efficacy in grade 3 stage IB lung adenocarcinoma.
Lung Cancer. 2025;202:108507.
PubMed Abstract available

TAKAMOCHI K, Suzuki K, Okada M, Niho S, et al
CRES(3)T: A single-arm confirmatory trial of S-1 plus cisplatin with concurrent radical-dose radiotherapy followed by surgery for superior sulcus tumors.
Lung Cancer. 2025;202:108506.
PubMed Abstract available

FAN M, Yan W, Zhuo M, Yu R, et al
Feasibility and safety of perioperative entrectinib in a patient with ROS1-positive locally advanced NSCLC: A case report.
Lung Cancer. 2025;202:108501.
PubMed Abstract available

MESSEKHER M, Fuchs F, Badr M, Pujol JL, et al
Gefitinib for EGFR mutated lung adenocarcinoma during pregnancy: A case report with 5-Year Follow-Up.
Lung Cancer. 2025;202:108456.
PubMed Abstract available

AHUJA G, Iyer A, Harwood R, Balata H, et al
Pathological & radiological variables in the diagnosis of bronchopulmonary carcinoids (BPCs) with a focus on Antigen Kiel 67 (Ki-67) proliferation index.
Lung Cancer. 2025;202:108493.
PubMed Abstract available

TORASAWA M, Yoshida T, Shiraishi K, Yagishita S, et al
Implications of EGFR expression on EGFR signaling dependency and adaptive immunity against EGFR-mutated lung adenocarcinoma.
Lung Cancer. 2025;202:108494.
PubMed Abstract available

LAVEN IEWG, Franssen AJPM, Gronenschild MHM, Heineman DJ, et al
National clinical practice patterns of uniportal video-assisted thoracoscopic anatomical lung resections: nationwide population-based data from a clinical audit registry.
Lung Cancer. 2025;202:108481.
PubMed Abstract available

GARASSINO MC, He Y, Ahn MJ, Orlov SV, et al
Osimertinib long-term tolerability in patients with EGFRm NSCLC enrolled in the AURA program or FLAURA study.
Lung Cancer. 2025;202:108417.
PubMed Abstract available

KAWAKITA N, Takehara E, Takeuchi T, Fujimoto K, et al
Advantages of a larger working channel diameter of ultrathin bronchoscope in cone-beam computed tomography-guided transbronchial biopsy for diagnosing peripheral lung lesions.
Lung Cancer. 2025;202:108483.
PubMed Abstract available

SOO RA, Vervita K, Fruh M, Cho BC, et al
A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance - The ETOP 15-19 ABC-lung trial.
Lung Cancer. 2025;202:108454.
PubMed Abstract available

March 2025

LINDBERG S, Grozman V, Karlsson K, Onjukka E, et al
Stereotactic body radiation therapy (SBRT) of centrally located medically inoperable early-stage non-small cell lung cancer (T1-T3N0M0) - A subgroup analysis of the expanded HILUS study.
Lung Cancer. 2025;203:108527.
PubMed Abstract available

LIU SV, Dziadziuszko R, Viteri S, Cappuzzo F, et al
ARTEMIA phase 3 study: A randomized, open-label trial comparing the efficacy and safety of OSE2101 versus docetaxel in HLA-A2 positive patients with metastatic non-small cell lung cancer and secondary resistance to immune checkpoint inhibitors.
Lung Cancer. 2025;203:108516.
PubMed

ADDO S, Lycan T, Soto-Pantoja DR, Tsai YT, et al
Randomized phase 2 trial of pembrolizumab alone or in combination with low dose chemotherapy for patients with non-small cell lung cancer and poor performance status.
Lung Cancer. 2025;203:108513.
PubMed Abstract available

NARGUND RS, Ishizawa S, Eghbalizarch M, Yeh P, et al
Natural history models for lung Cancer: A scoping review.
Lung Cancer. 2025;203:108495.
PubMed Abstract available

ISAKA M, Notsu A, Kojima H, Konno H, et al
Comparative validation of nodal classifications in resected non-small cell lung cancer based on the anatomical location and number of involved stations.
Lung Cancer. 2025;203:108511.
PubMed Abstract available

KESKIN O
Beyond the Staging: Critical Insights into the Ninth TNM Edition for Lung Cancer.
Lung Cancer. 2025;203:108502.
PubMed

TRIWIYANTO T, Alit Pawana I, Luthfiyah S
Commentary on: Identification of key gene signatures for predicting chemo-immunotherapy efficacy in extensive-stage small-cell lung cancer using machine learning.
Lung Cancer. 2025;202:108512.
PubMed

CHEN H, Cai W, Han Y, Zhao Y, et al
Associations between carbohydrate quality and the survival of, and life expectancy with lung cancer patient: A prospective cohort study.
Lung Cancer. 2025;203:108508.
PubMed Abstract available

BOUSEMA JE, Spaans LN, Dijkgraaf MGW, van der Heijden EHFM, et al
Two-year survival and disease recurrence after endosonography with or without confirmatory mediastinoscopy for resectable lung cancer (a short communication of the MEDIASTrial follow-up).
Lung Cancer. 2025;202:108462.
PubMed Abstract available

HEMMINKI K, Zitricky F, Sundquist K, Sundquist J, et al
Lung cancer risk between maternal and paternal half-siblings points to main environmental causation and targets for prevention.
Lung Cancer. 2025;202:108500.
PubMed Abstract available

GOTO Y, Watanabe S, Yanagimura N, Arita M, et al
The diagnostic value of comprehensive next-generation sequencing for genetic mutations in suspected lung cancer cases with negative pathological cytology.
Lung Cancer. 2025;202:108505.
PubMed Abstract available

GOBBINI E, Diallo MH, Pasquier D, Schneider S, et al
Clinical characteristics and management of long survivors in extensive stage small cell lung cancer.
Lung Cancer. 2025;202:108499.
PubMed Abstract available

JABER G, Raffoul C, Diab T, Sinno S, et al
ALK-EML4 Fusion in Small Cell Lung Cancer: Clinical and Molecular Insights From a Rare Case.
Lung Cancer. 2025;202:108497.
PubMed Abstract available

CHO BC, Hayashi H, Lee JS, Lee SH, et al
Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset.
Lung Cancer. 2025;204:108496.
PubMed Abstract available

VAN DER WEL JWT, de Langen AJ
Novel strategies for rare oncogenic drivers in non-small-cell lung cancer: An update from the 2024 Annual ESMO meeting.
Lung Cancer. 2025 Mar 14:108490. doi: 10.1016/j.lungcan.2025.108490.
PubMed Abstract available

NAVEED F, Khan S, Khan A, Arshad F, et al
Letter: Alectinib combined with cobimetinib in ALK-rearranged lung cancer: A phase IB study.
Lung Cancer. 2025;202:108489.
PubMed

NOUSIAS O, Mandell JD, Anderson KS, Townsend JP, et al
Precision projections of the delay of resistance mutations in non-small cell lung cancer via suppression of APOBEC.
Lung Cancer. 2025;202:108487.
PubMed Abstract available

SETO T, Nakane S, Ji L, Ueda Y, et al
Real-world safety and effectiveness of entrectinib in Japanese patients with ROS1 gene fusion-positive, unresectable, advanced/recurrent non-small cell lung cancer: Post-marketing surveillance.
Lung Cancer. 2025;203:108478.
PubMed Abstract available

VERKOULEN KCHA, Laven IEWG, Daemen JHT, Franssen AJPM, et al
From data to prediction: Digital chest drain insights into postoperative recovery after lung cancer surgery.
Lung Cancer. 2025;202:108486.
PubMed Abstract available

CHO BC, Johnson M, Bar J, Schaefer E, et al
A phase 1b study of cofetuzumab pelidotin monotherapy in patients with PTK7-expressing recurrent non-small cell lung cancer.
Lung Cancer. 2025;202:108492.
PubMed Abstract available

COOKE S, Nelson D, Argin AA, Laparidou D, et al
Identifying and exploring patient engagement interventions for people diagnosed with lung cancer: A rapid systematic review.
Lung Cancer. 2025;202:108484.
PubMed Abstract available

VINAS F, Goussault H, Boyer L, Bussac GR, et al
Evaluation of teleguided high-intensity exercise rehabilitation at home before lung-cancer surgery (PREPACHIR Study).
Lung Cancer. 2025;202:108480.
PubMed Abstract available

FROST MG, Jensen KJ, Jimenez-Solem E, Qvortrup C, et al
Sex disparities in advanced non-small cell lung cancer survival: A Danish nationwide study.
Lung Cancer. 2025;202:108485.
PubMed Abstract available

GRIDELLI C, Attili I, Bennati C, Bironzo P, et al
Immunotherapy in advanced non-small cell lung cancer: What to do for the 'Invisible' patients after IPSOS trial results?
Lung Cancer. 2025;202:108482.
PubMed Abstract available

IGLESIAS MARTINEZ B, Insa A, Cervera Ygual G, Gascon F, et al
Use of immune checkpoint inhibitors in patients with lung cancer and multiple sclerosis.
Lung Cancer. 2025;202:108464.
PubMed Abstract available

UEHARA Y, Izumi H, Kobayashi IS, Matsumoto S, et al
Efficacy of EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer with EGFR exon 19 insertions: clinical-genomic, preclinical analysis through LC-SCRUM-Asia (multi-institutional genomic screening registry).
Lung Cancer. 2025;202:108479.
PubMed Abstract available

GROS L, Yip R, Flores RM, Zhang J, et al
Prospective cohort study of Suture-Line recurrence and clinical outcomes in stage 1A Non-Small cell lung cancer.
Lung Cancer. 2025;202:108465.
PubMed Abstract available

ZHANG M, Deng C, Fu F, Li Y, et al
Site-specific follow-up strategy for surgically resected patients with NSCLC based on ten-year follow-up data.
Lung Cancer. 2025;201:108451.
PubMed Abstract available

MORIMOTO K, Yamada T, Furuya N, Tanaka H, et al
Exploration of clinical Biomarkers for guiding treatment selection between chemotherapy and combination therapy with Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-Mutant NSCLC patients after EGFR-TKI Therapy: The SPIRAL-STEP study.
Lung Cancer. 2025;201:108447.
PubMed Abstract available

CHOI W, Lee W, Kim Y, Lee SJ, et al
Immune landscape and novel therapeutic targets of epidermal growth factor receptor and anaplastic lymphoma kinase wild type never-smoker lung adenocarcinoma.
Lung Cancer. 2025;201:108448.
PubMed Abstract available

SUBRAMANIAN J, Gregg J, Berktas M, Li J, et al
EGFR testing practices, treatment choice and clinical outcomes in advanced NSCLC in a real-world setting: A retrospective analysis of a US-based electronic health records database.
Lung Cancer. 2025;201:108412.
PubMed Abstract available

CAMIDGE DR, Sugawara S, Kondo M, Kim HR, et al
Efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK+ NSCLC: Integrated analysis of the ALTA-1L and J-ALTA trials.
Lung Cancer. 2025;201:108424.
PubMed Abstract available

YAO Z, Qiu T, Li C, Kong W, et al
Primary pulmonary adenoid cystic carcinoma: A study of clinicopathological features and molecular alterations in twenty-one cases.
Lung Cancer. 2025;201:108414.
PubMed Abstract available

YANG R, Wang H, Liu D, Li W, et al
Prevalence and prognostic significance of interstitial lung abnormalities in lung cancer: A meta-analysis.
Lung Cancer. 2025;205:108458.
PubMed Abstract available

February 2025

SAW SPL, Takano A, Zhou S, Hlaing NO, et al
EGFR mutation status affects intra-tumoural heterogeneity of PD-L1 expression but not agreement between assays in resectable non-small cell lung cancer.
Lung Cancer. 2025;202:108463.
PubMed Abstract available

YANG YH, Kim HE, Park BJ, Lee JG, et al
Patterns and preoperative risk factors of occult lymph node metastasis in clinical stage I lung cancer.
Lung Cancer. 2025;202:108461.
PubMed Abstract available

MA Z, Fu F, Zhang Y, Chen H, et al
Long-term outcomes of neoadjuvant gefitinib in resectable stage II-IIIA non-small cell lung cancer: A phase II, prospective cohort study.
Lung Cancer. 2025;201:108457.
PubMed Abstract available

BAUMAN JR, Liu G, Preeshagul I, Liu SV, et al
Corrigendum to "Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer" [Lung Cancer 195 (2024) 107919].
Lung Cancer. 2025 Feb 22:108441. doi: 10.1016/j.lungcan.2025.108441.
PubMed

JOHNSON M, Younan D, Kent ST, Frias MM, et al
Corrigendum to "Real-world comparative effectiveness of sotorasib versus docetaxel in second line and beyond among patients with advanced non-small cell lung cancer (NSCLC)" [Lung Cancer 197 (2024) 107960].
Lung Cancer. 2025 Feb 20:108440. doi: 10.1016/j.lungcan.2025.108440.
PubMed

LEE K, Kim TH, Yong Lee S, Lee YG, et al
Delayed central nervous system progression with atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer (LU23-15).
Lung Cancer. 2025;201:108455.
PubMed Abstract available

GIRARD N, Han JY, Soo RA, Wang K, et al
Comparative effectiveness and safety of tislelizumab versus other anti-PD-(L)1 agents in first- and subsequent lines in locally advanced or metastatic non-small cell lung cancer: Systematic literature review and network meta-analysis.
Lung Cancer. 2025;201:108450.
PubMed Abstract available

SATOH H, Okuma Y, Shinno Y, Masuda K, et al
Evolving treatments and prognosis in Stage IV non-small cell lung cancer: 20 years of progress of novel therapies.
Lung Cancer. 2025;202:108453.
PubMed Abstract available

FENG J, Hueniken K, Fan ZJ, Zhan LJ, et al
Prognostic and predictive effects of TP53 co-mutation in patients with non-small cell lung cancer with rare treatable driver mutations.
Lung Cancer. 2025;204:108452.
PubMed Abstract available

SANKAR K, Mercer J, Jaeger EB, Godden J, et al
DNA damage repair gene alterations influence the tumor immune microenvironment in advanced non-small cell lung cancer.
Lung Cancer. 2025;201:108444.
PubMed Abstract available

SHAHNAM A, Davis A, Brown LJ, Sullivan I, et al
Real-World outcomes of Non-Small cell lung cancer patients harbouring KRAS G12C and KRAS G12D mutations.
Lung Cancer. 2025;201:108421.
PubMed Abstract available

AHN B, Kim D, Ji W, Chun SM, et al
Clinicopathologic and genomic analyses of SMARCA4-mutated non-small cell lung carcinoma implicate the needs for tailored treatment strategies.
Lung Cancer. 2025;201:108445.
PubMed Abstract available

HUANG L, Petersen RH
Tumour spread through air spaces is a determiner for treatment of clinical stage I non-small cell lung Cancer: Thoracoscopic segmentectomy vs lobectomy.
Lung Cancer. 2025;201:108438.
PubMed Abstract available

BOSCH-BARRERA J, Estevez-Garcia P, Martin-Martorell P, Sabatier R, et al
ENDOLUNG trial, part II. A phase II study of the Akt/mTOR inhibitor and autophagy inducer ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with squamous non-small cell lung cancer.
Lung Cancer. 2025;201:108105.
PubMed Abstract available

AKAMATSU H, Nishikawa T, Takeda Y, Misumi T, et al
Longitudinal recurrence risk of adjuvant cytotoxic chemotherapy and gefitnib in resected lung cancer: A combined analysis of phase III studies.
Lung Cancer. 2025;201:108437.
PubMed Abstract available

HE Q, Jiang L, Xu Y, Wang M, et al
Evaluating the safety of antibody-drug conjugates in lung cancer: A systematic review and meta-analysis.
Lung Cancer. 2025;201:108425.
PubMed Abstract available

ATASEVER F, Sokucu SN, Satici C
Letter to the editor concerning "Comparison of radiotherapy versus surgical resection following neoadjuvant chemoimmunotherapy in potentially resectable stage III non-small-cell lung cancer: A propensity score matching analysis".
Lung Cancer. 2025;201:108423.
PubMed

FICARRA S, Kang DW, Wilson RL, Gonzalo-Encabo P, et al
Exercise medicine for individuals diagnosed with Lung Cancer: A systematic review and meta-analysis of health outcomes.
Lung Cancer. 2025;201:108413.
PubMed Abstract available

UPRETY D, Abrahami D, Marcum ZA, Li B, et al
Brain metastases and mortality in patients with ALK + metastatic non-small cell lung cancer treated with second-generation ALK tyrosine kinase inhibitors as first-line targeted therapies: An observational cohort study.
Lung Cancer. 2025;201:108436.
PubMed Abstract available

TAMBO Y, Sone T, Nishi K, Shibata K, et al
Five-year efficacy and safety of pembrolizumab as first-line treatment in patients with non-small cell lung cancer with PD-L1 tumor proportion score >/=50 %: A multicenter observational study.
Lung Cancer. 2025;201:108422.
PubMed Abstract available

SUMI T, Ishigooka T, Matsuura K, Ikeda T, et al
Dual onsets of small cell lung cancer with contrasting neuroendocrine features and immune microenvironments: A case report.
Lung Cancer. 2025;201:108420.
PubMed Abstract available

WANG Y, Fujita RA, Fujisawa N, Laskin J, et al
Mitigation of decline with virtual exercise with lung cancer (MoVE with lung cancer) - A promising approach to enhance physiological strength, improve body composition, and build upon current evidence.
Lung Cancer. 2025;201:108418.
PubMed Abstract available

IKEDA S, Ogura T, Miyaoka E, Sekine I, et al
Survival benefit and potential markers of chemotherapy for elderly and poor performance status patients with advanced non-small cell lung cancer: Results from the Japanese Joint Committee of lung cancer registry database.
Lung Cancer. 2025;200:108102.
PubMed Abstract available

REUSS JE, Zaemes J, Gandhi N, Walker P, et al
Comprehensive molecular profiling of squamous non-small cell lung cancer reveals high incidence of actionable genomic alterations among patients with no history of smoking.
Lung Cancer. 2025;200:108101.
PubMed Abstract available

HATA T, Yamada T, Goto Y, Amano A, et al
Comparative analysis of first-line treatment in NSCLC including unresectable stage III (IIIB/IIIC) and stage IV with low PD-L1 expression: Clinical trial eligible versus ineligible patients.
Lung Cancer. 2025;200:108104.
PubMed Abstract available

NARITA D, Hishinuma E, Ebina-Shibuya R, Miyauchi E, et al
Histological and genetic features and therapeutic responses of lung cancers explored via the global analysis of their metabolome profile.
Lung Cancer. 2025;200:108082.
PubMed Abstract available

GOMEZ-RANDULFE I, Scanlon LA, Carter M, Moliner L, et al
First-line osimertinib compared to earlier generation TKIs in advanced EGFR-mutant NSCLC: A real-world survival analysis.
Lung Cancer. 2025;200:108084.
PubMed Abstract available

January 2025

DOBKIN J, Stanifer BP, Salvatore M, Eckhardt CM, et al
Evaluating lung cancer risk factors in adults with interstitial lung disease.
Lung Cancer. 2025;201:108416.
PubMed Abstract available

NISHI T, Morita A, Hara N, Makimoto G, et al
Efficacy of amivantamab, a bi-specific antibody targeting EGFR and MET, in ALK-rearranged non-small-cell lung cancer cell lines.
Lung Cancer. 2025;201:108415.
PubMed Abstract available

LIU T, He J, Wang Y, Yang Y, et al
Health-related quality of life and symptoms in patients with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer treated with sintilimab or placebo plus pemetrexed and platinum (ORIENT-11): A randomized, double
Lung Cancer. 2025;200:108108.
PubMed Abstract available

HOFMAN P, Ourailidis I, Romanovsky E, Ilie M, et al
Artificial intelligence for diagnosis and predictive biomarkers in Non-Small cell lung cancer Patients: New promises but also new hurdles for the pathologist.
Lung Cancer. 2025;200:108110.
PubMed Abstract available

HOFMAN P, Christopoulos P, D'Haene N, Gosney J, et al
Proposal of real-world solutions for the implementation of predictive biomarker testing in patients with operable non-small cell lung cancer.
Lung Cancer. 2025;201:108107.
PubMed Abstract available

AHMAD SQ, Pesola F, Crosbie PAJ, Gabe R, et al
Adherence to community-based lung cancer screening in the Yorkshire Lung Screening Trial.
Lung Cancer. 2025;200:108086.
PubMed Abstract available

LEE KH, Lee JS, Sugawara S, Kang JH, et al
First-line nivolumab plus platinum chemotherapy and bevacizumab for advanced nonsquamous non-small cell lung cancer: A 3-year follow-up of the phase 3 randomized TASUKI-52 trial.
Lung Cancer. 2025;201:108109.
PubMed Abstract available

MUNOZ OM, Delgado Leon BD, Selles EG, Enguix-Riego MV, et al
Association of single nucleotide polymorphisms rs7459185 of the HSPbeta1 gene and the risk of hematological toxicity in lung cancer.
Lung Cancer. 2025;200:108103.
PubMed Abstract available

GRIDELLI C, Mok T, Janne P, Passaro A, et al
Debate on first-line treatment strategies in advanced non-small cell lung cancer with EGFR mutation: An expert panel meeting by the Italian Association of Thoracic Oncology (AIOT).
Lung Cancer. 2025;201:108100.
PubMed Abstract available

FUJII K, Ueki M, Morishita M, Ikushima H, et al
Clinical utility of comprehensive genomic profiling in non-small cell lung cancer: An analysis of a nation-wide database.
Lung Cancer. 2025;200:108099.
PubMed Abstract available

MULLALLY WJ, O'Leary CG, O'Byrne KJ
Rearranged during transfection (RET) lung cancer - Update on targeted therapies.
Lung Cancer. 2025;200:108083.
PubMed Abstract available

DECOSTER L, Camidge DR, Fletcher JA, Addeo A, et al
Targeted therapy for older patients with an oncogene driven non-small cell lung cancer: Recommendations from a SIOG expert group.
Lung Cancer. 2025;200:108087.
PubMed Abstract available

WU L, Tian JY, Li MJ, Jiang F, et al
Validation of the 9th edition of the TNM staging system for limited-stage small cell lung cancer after Resection: A multicenter study.
Lung Cancer. 2025;200:108085.
PubMed Abstract available

TESEMA GA, Stirling RG, Wah W, Tessema ZT, et al
Geographic variation in delay to surgical treatment among non-small cell lung cancer patients.
Lung Cancer. 2025;199:108077.
PubMed Abstract available

LI Y, Law J, Le LW, Li JJN, et al
Assessing the feasibility and external validity of natural language processing-extracted data for advanced lung cancer patients.
Lung Cancer. 2025;199:108080.
PubMed Abstract available

WU Y, Tang Y, Huang W, Zhu C, et al
Improving the screening ability of neuron-specific enolase on small cell lung cancer.
Lung Cancer. 2025;199:108078.
PubMed Abstract available

FUJIMOTO D, Shibaki R, Kimura K, Haratani K, et al
Identification of key gene signatures for predicting chemo-immunotherapy efficacy in extensive-stage small-cell lung cancer using machine learning.
Lung Cancer. 2025;199:108079.
PubMed Abstract available

SAW SPL, Zhong WZ, Fu R, Li MSC, et al
Asian Thoracic Oncology Research Group expert consensus statement on the peri-operative management of non-small cell lung cancer.
Lung Cancer. 2025;200:108076.
PubMed Abstract available

NANAMI H, Matsumoto Y, Furuse H, Tanaka M, et al
Efficacy of cryobiopsy during medical thoracoscopy for diagnosing malignant pleural mesothelioma.
Lung Cancer. 2025;199:108074.
PubMed Abstract available

THUNNISSEN E, Blaauwgeers H, Filipello F, Lissenberg-Witte B, et al
A reproducibility study on invasion in small pulmonary adenocarcinoma according to the WHO and a modified classification, supported by biomarkers.
Lung Cancer. 2025;199:108060.
PubMed Abstract available

TSUI DCC, Lee JK, Tambaoan CFB, Hughes J, et al
Genomic analysis of comprehensive next generation sequencing data to explore the criteria for MET amplification as an actionable biomarker in NSCLC.
Lung Cancer. 2025;199:108081.
PubMed Abstract available

WU M, Zhou N, Guan M, Wang Y, et al
Efficacy of immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma and predictive potential of mutated TP53.
Lung Cancer. 2025;199:108068.
PubMed Abstract available

SHIELDS MD, Minton KG, Tran M, Gunderman PR, et al
Defining the needle in a haystack: A compendium of genomic, pathologic, and clinical characteristics of rare pulmonary tumors.
Lung Cancer. 2025;199:108035.
PubMed Abstract available

VOLMONEN KK, Ronty MJ, Sederholm A, Paajanen JI, et al
Evaluating tumour budding could improve the new grading system for lung adenocarcinoma.
Lung Cancer. 2025;199:108067.
PubMed Abstract available

LEI M, Zhang X, Hu LN, Fu S, et al
Perioperative immunotherapy plus chemotherapy versus chemotherapy alone for patients with resectable pulmonary lymphoepithelioma-like carcinoma.
Lung Cancer. 2025;199:108057.
PubMed Abstract available

DE GIGLIO A, De Biase D, Favorito V, Maloberti T, et al
STK11 mutations correlate with poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status.
Lung Cancer. 2025;199:108058.
PubMed Abstract available

HE L, Zhang B, Zhou C, Zhao Q, et al
A combined model of circulating tumor DNA methylated SHOX2/SCT/HOXA7 and clinical features facilitates the discrimination of malignant from benign pulmonary nodules.
Lung Cancer. 2025;199:108064.
PubMed Abstract available

December 2024

OGLIARI FR, Traverso A, Barbieri S, Montagna M, et al
Exploring machine learning tools in a retrospective case-study of patients with metastatic non-small cell lung cancer treated with first-line immunotherapy: A feasibility single-centre experience.
Lung Cancer. 2024;199:108075.
PubMed Abstract available

NAKAO M, Suzuki A, Ichinose J, Matsuura Y, et al
Prognostic impact of the N2 subclassification and stage migration in the ninth edition of the TNM classification in surgically resected lung cancer.
Lung Cancer. 2024;199:108073.
PubMed Abstract available

AGUADO-BARRERA ME, Lopez-Pleguezuelos C, Gomez-Caamano A, Calvo-Crespo P, et al
Professional-patient discrepancies in assessing lung cancer radiotherapy symptoms: An international multicentre study.
Lung Cancer. 2024;199:108072.
PubMed Abstract available

HARRIS RA, Stokes EA, Batchelor TJP, Internullo E, et al
Optimum diagnostic pathway and pathologic confirmation rate of early stage lung cancer: Results from the VIOLET randomised controlled trial.
Lung Cancer. 2024;199:108070.
PubMed Abstract available

SZTANKOVICS D, Szalai F, Moldvai D, Danko T, et al
Comparison of molecular subtype composition between independent sets of primary and brain metastatic small cell lung carcinoma and matched samples.
Lung Cancer. 2024;199:108071.
PubMed Abstract available

WELLER M, Le Rhun E, Tsamtsouri L, Dummer R, et al
Immunotherapy or targeted therapy with or without stereotactic radiosurgery for patients with brain metastases from melanoma or non-small cell lung cancer - The ETOP 19-21 USZ-STRIKE study.
Lung Cancer. 2024;199:108069.
PubMed

SUAZO-ZEPEDA E, Viddeleer AR, Maas WJ, Postmus D, et al
CT-assessed sarcopenia and immune-related adverse events in patients with lung cancer: A competing risk time-to-event analysis.
Lung Cancer. 2024;199:108054.
PubMed Abstract available

ZERDES I, Kamali C, Johannsdottir B, Blasi M, et al
A novel clinical brain prognostic index for KRAS-mutated lung cancer and brain metastases (KRAS-BPI): Real-world evidence from two large European centers.
Lung Cancer. 2024;199:108065.
PubMed Abstract available

MA Z, Liu Y, Bao Y, Wang M, et al
Impact of locoregional recurrence versus distant metastasis on overall survival in patients with Non-Small cell lung cancer after Surgery: A secondary analysis of PORT-C RCT.
Lung Cancer. 2024;199:108063.
PubMed Abstract available

DONG Y, Yang G, Yang Y, Zhang S, et al
Dynamic characterization of circulating tumor DNA in HER2-altered advanced non-small cell lung cancer treated with pyrotinib and apatinib: Exploratory biomarker analysis from PATHER2 study.
Lung Cancer. 2024;200:108062.
PubMed Abstract available

HOUDA I, Bahce I, Dickhoff C, Kroese TE, et al
An international and multidisciplinary EORTC survey on resectability of stage III non-small cell lung cancer.
Lung Cancer. 2024;199:108061.
PubMed Abstract available

GELSOMINO F, Boni L, Tiseo M, Ricciardi S, et al
An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy-EDEN trial GOIRC 04-201
Lung Cancer. 2024;199:108059.
PubMed Abstract available

SUGISAKA J, Fujimoto D, Tamiya M, Hata A, et al
Long-term outcome of chemoimmunotherapy for extensive-stage small-cell lung cancer according to key clinical trial eligibility: 3-year outcomes from a prospective cohort study.
Lung Cancer. 2024;199:108056.
PubMed Abstract available

URTECHO SB, Provenzano L, Spagnoletti A, Bottiglieri A, et al
Decoding KRAS mutation in non-small cell lung cancer patients receiving immunotherapy: A retrospective institutional comparison and literature review.
Lung Cancer. 2024;199:108051.
PubMed Abstract available

WANG M, Xu Y, Huang WT, Su WC, et al
Sunvozertinib monotherapy in EGFR tyrosine kinase inhibitor-resistant non-small cell lung cancer with EGFR mutations.
Lung Cancer. 2024;199:108053.
PubMed Abstract available

KARAYAMA M, Suda T, Yoh K, Usui K, et al
Difference in efficacy of osimertinib between patients with EGFR-positive NSCLC with postoperative recurrence and those with de novo unresectable disease: A prospective, observational study.
Lung Cancer. 2024;198:108037.
PubMed Abstract available

FERNANDEZ-BUSSY S, Funes-Ferrada R, Yu Lee-Mateus A, Vaca-Cartagena BF, et al
Diagnostic performance of Shape-Sensing Robotic-Assisted bronchoscopy with mobile Cone-Beam CT for cystic and cavitary pulmonary lesions.
Lung Cancer. 2024;198:108029.
PubMed Abstract available

JOHN A, McMahon DJ, Chauhan D, Mullings S, et al
Lorlatinib-associated weight gain and dyslipidaemia: A retrospective analysis and implications for future care.
Lung Cancer. 2024;198:108034.
PubMed Abstract available

AYOADE O, Canavan ME, Caturegli G, Boffa DJ, et al
Brief Report: Should a prior cancer history be reevaluated as an exclusion for clinical trial participation?
Lung Cancer. 2024;198:108032.
PubMed Abstract available

HEIJBOER FWJ, Mulders TA, van Straten M, Moonen L, et al
Radiological follow-up in patients with resected pulmonary carcinoids: Should we reduce radiation exposure?
Lung Cancer. 2024;198:108030.
PubMed Abstract available

VAN DER WEL JWT, Jebbink M, van den Broek D, Steinbusch LC, et al
Combined analysis of circulating tumor DNA and tumor tissue to overcome osimertinib resistance (OSIRIS); the second line osimertinib cohort.
Lung Cancer. 2024;198:107972.
PubMed Abstract available

WANG L, Song B, Zhang Z, Bo B, et al
Evaluating efficacy and safety of a novel registration-free CT-guided needle biopsy navigation system (RC 120): A multicenter, prospective clinical trial.
Lung Cancer. 2024;198:108025.
PubMed Abstract available

SANTARPIA M, Aliprandi M, Claudia Spagnolo C, Avan A, et al
NOTCH and PTP4A3 alterations emerge as novel predictive biomarkers and potential therapeutic targets in pleural mesothelioma.
Lung Cancer. 2024;198:108024.
PubMed Abstract available

November 2024

SWALDUZ A, Beau-Faller M, Planchard D, Mazieres J, et al
Real-world efficacy of the dabrafenib-trametinib (D-T) combination in BRAF V600E-mutated metastatic non-small cell lung cancer (NSCLC): Results from the IFCT-2004 BLaDE cohort.
Lung Cancer. 2024;199:108038.
PubMed Abstract available

AUCLIN E, Roulleaux Dugage M, Gorria T, Vauchier C, et al
Validation of the Lung Immune Prognostic Index in patients with untreated advanced non-small cell lung cancer: Post hoc analysis of the IMpower 130, 131 and 150 trials.
Lung Cancer. 2024;199:108039.
PubMed Abstract available

PATIL T, Gao D, Watson A, Sakamoto M, et al
The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon progression in patients with metastatic non-small cell lung cancer harboring sensitizing EGFR mutations.
Lung Cancer. 2024;199:108040.
PubMed Abstract available

JUNG W, Cho IY, Jeon KH, Yeo Y, et al
Addressing knowledge and attitude barriers to lung cancer screening: Development and evaluation of web-based decision aid.
Lung Cancer. 2024;198:108031.
PubMed Abstract available

ZENG H, Schagen SB, Hendriks LEL, Sanchez-Benavides G, et al
Impact of HA-PCI on self-reported cognitive functioning and brain metastases in small-cell lung cancer: Pooled findings of NCT01780675 and PREMER trials.
Lung Cancer. 2024;199:108036.
PubMed Abstract available

YU Z, Zou J, Xu F
The molecular subtypes of small cell lung cancer defined by key transcription factors and their clinical significance.
Lung Cancer. 2024;198:108033.
PubMed Abstract available

BAHADORI S, Hosseini M
Use of commercial WAMs for monitoring individual with lung cancer. A systematic review.
Lung Cancer. 2024;198:108026.
PubMed Abstract available

OSATAPHAN S, Awidi M, Jan YJ, Gunturu K, et al
Association between higher glucose levels and reduced survival in patients with non-small cell lung cancer treated with immune checkpoint inhibitors.
Lung Cancer. 2024;198:108023.
PubMed Abstract available

HORINOUCHI H, Murakami H, Harada H, Sobue T, et al
Real-world status of multimodal treatment of Stage IIIA-N2 non-small cell lung cancer in Japan: Results from the SOLUTION study, a non-interventional, multicenter cohort study.
Lung Cancer. 2024;199:108027.
PubMed Abstract available

KOSAKA N, Kataoka Y
Letter regarding "The significance of inflammatory markers in prognosticating the effectiveness and safety of immunotherapy in conjunction with chemotherapy during the primary intervention of advanced non-small cell lung carcinoma".
Lung Cancer. 2024;198:108020.
PubMed

YU Y, Fan Y, Dong X, Li J, et al
Entrectinib versus crizotinib in Asian patients with ROS1-positive non-small cell lung cancer: A matching-adjusted indirect comparison.
Lung Cancer. 2024;198:108018.
PubMed Abstract available

LIU H, Hong Q, Zheng S, Zhang M, et al
Effective treatment strategies and key factors influencing therapeutic efficacy in advanced SMARCA4-deficient non-small cell lung cancer.
Lung Cancer. 2024;198:108022.
PubMed Abstract available

AKAMATSU H, Koh Y, Nishio M, Goto Y, et al
Comprehensive serum biomarker analysis reveals IL-8 changes as the only predictor of the effectiveness of immune checkpoint inhibitors for patients with advanced non-small cell lung cancer.
Lung Cancer. 2024;198:108017.
PubMed Abstract available

ZHANG B, Bao H, Li Z, Chen J, et al
Continuing immune checkpoint inhibitors after progression: Real-world patterns of care and outcomes in second-line treatment for extensive-stage small-cell lung cancer.
Lung Cancer. 2024;199:108021.
PubMed Abstract available

DONG J, Bao H
Comment on: Efficacy and safety of crizotinib in the treatment of advanced non-small cell lung cancer with ROS1 gene fusion: A systematic literature review and meta-analysis of real-world evidence.
Lung Cancer. 2024;201:108019.
PubMed

BAUMAN JR, Liu G, Preeshagul I, Liu SV, et al
Corrigendum to "Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK -positive advanced non-small cell lung cancer" [Lung Cancer 195 (2024) 107919].
Lung Cancer. 2024 Nov 1:108000. doi: 10.1016/j.lungcan.2024.108000.
PubMed

TU X, Lu Z, Hei F, Zhang T, et al
Putative mechanisms of primary resistance to EGFR-targeted therapies: A retrospective study.
Lung Cancer. 2024;197:107998.
PubMed Abstract available

HE X, Yang Z, Wu F, Liang Q, et al
Confronting synchronous multiple primary lung cancers: Navigating the intersection of challenges and opportunities.
Lung Cancer. 2024;197:107994.
PubMed Abstract available

FILIPELLO F, Blaauwgeers H, Lissenberg-Witte B, Schonau A, et al
Stereologic consequences of iatrogenic collapse: The morphology of adenocarcinoma in situ overlaps with invasive patterns. Proposal for a necessary modified classification of pulmonary adenocarcinomas.
Lung Cancer. 2024;197:107987.
PubMed Abstract available

XU D, Liang SQ, Su M, Yang H, et al
Crispr-mediated genome editing reveals a preponderance of non-oncogene addictions as targetable vulnerabilities in pleural mesothelioma.
Lung Cancer. 2024;197:107986.
PubMed Abstract available

ZWIERENGA F, Zhang L, Melcr J, Schuuring E, et al
The prediction of treatment outcome in NSCLC patients harboring an EGFR exon 20 mutation using molecular modeling.
Lung Cancer. 2024;197:107973.
PubMed Abstract available

TABE C, Fujita T, Taima K, Tanaka H, et al
Highly sensitive and accurate detection of ALK-TKI resistance mutations by oligoribonucleotide interference-PCR (ORNi-PCR)-based methods.
Lung Cancer. 2024;197:107969.
PubMed Abstract available

SNIDER M, Salama JK, Boyer M
Survival and recurrence rates following SBRT or surgery in medically operable Stage I NSCLC.
Lung Cancer. 2024;197:107962.
PubMed Abstract available

BRUNE MM, Savic Prince S, Vlajnic T, Chijioke O, et al
MTAP as an emerging biomarker in thoracic malignancies.
Lung Cancer. 2024;197:107963.
PubMed Abstract available

UCHIBORI A, Okada S, Shimomura M, Furuya T, et al
Clinical impact of preoperative sarcopenia and immunonutritional impairment on postoperative outcomes in non-small cell lung cancer surgery.
Lung Cancer. 2024;198:108004.
PubMed Abstract available

DAGOGO-JACK I, Cooper AJ, Johnson BE, Gainor JF, et al
Alectinib combined with cobimetinib in ALK-Rearranged lung Cancer: A phase IB study.
Lung Cancer. 2024;199:108003.
PubMed Abstract available

October 2024

VINCE M, Naqvi SMH, Pellini B, Verbosky M, et al
Real-world comparison of the efficacy and safety of atezolizumab versus durvalumab in extensive-stage small cell lung cancer.
Lung Cancer. 2024;198:107999.
PubMed Abstract available

PISAPIA P, Russo A, De Luca C, Pepe F, et al
The relevance of the reference range for EGFR testing in non-small cell lung cancer patients.
Lung Cancer. 2024;198:108002.
PubMed Abstract available

PANG J, Zhang Y, Wang X, Wu W, et al
Clinical benefit evaluation of drug treatment regimens for advanced lung cancer:based on ASCO-VF and ESMO-MCBS.
Lung Cancer. 2024;197:108001.
PubMed Abstract available

CHAN YH, Yuen-Ting C, Sin CF, Ma ESK, et al
Treatment with trimetazidine dihydrochloride and lung cancer survival: Implications on metabolic re-programming.
Lung Cancer. 2024;197:107996.
PubMed Abstract available

AY L, Steiner D, Fabikan H, Illini O, et al
Neoadjuvant therapy in early-stage non-small cell lung cancer: A real-world analysis.
Lung Cancer. 2024;198:107997.
PubMed Abstract available

LEVY A, Berghmans T, Koller M, Fournier B, et al
PRIMALung (EORTC-1901): PRophylactic cerebral irradiation (PCI) or active brain MAgnetic resonance imaging (MRI) surveillance in small-cell lung cancer (SCLC) patients.
Lung Cancer. 2024;198:107993.
PubMed Abstract available

BERTOLACCINI L, Tralongo AC, Del Re M, Facchinetti F, et al
Segmentectomy vs. Lobectomy in stage IA non-small cell lung cancer: A systematic review and meta-analysis of perioperative and survival outcomes.
Lung Cancer. 2024;197:107990.
PubMed Abstract available

TEIXIDOR-VILA E, Trallero J, Puigdemont M, Vidal-Vila A, et al
Lung cancer survival trends and prognostic factors: A 26-year population-based study in Girona Province, Spain.
Lung Cancer. 2024;197:107995.
PubMed Abstract available

BAI Z, Cheng X, Ma T, Li G, et al
CD8+ T cells infiltrating into tumors were controlled by immune status of pulmonary lymph nodes and correlated with non-small cell lung cancer (NSCLC) patients' prognosis treated with chemoimmunotherapy.
Lung Cancer. 2024;197:107991.
PubMed Abstract available

KATO Y, Udagawa H, Matsumoto S, Izumi H, et al
Efficacy of immune checkpoint inhibitors plus platinum-based chemotherapy as 1st line treatment for patients with non-small cell lung cancer harboring HER2 mutations: Results from LC-SCRUM-Asia.
Lung Cancer. 2024;197:107992.
PubMed Abstract available

HATA A, Katakami N, Takase N, Kibata K, et al
Afatinib plus bevacizumab combination after osimertinib resistance in advanced EGFR-mutant non-small cell lung cancer: Phase II ABCD-study.
Lung Cancer. 2024;197:107988.
PubMed Abstract available

LI M, Soo RA
Can therapeutic drug monitoring of lorlatinib help us design the right CROWN?
Lung Cancer. 2024;196:107965.
PubMed

CHEN M, Huang Y, Jiang S, Ke C, et al
Safety assessment of KRAS (G12C) inhibitors based on the FDA Adverse Event Reporting System (FAERS) database: A real-world pharmacovigilance study.
Lung Cancer. 2024;196:107966.
PubMed Abstract available

ABIA-TRUJILLO D, Funes-Ferrada R, Yu Lee-Mateus A, Barrios-Ruiz A, et al
Cryobiopsy versus fine-needle aspiration for shape-sensing robotic-assisted sampling of small lung nodules.
Lung Cancer. 2024;196:107967.
PubMed Abstract available

SHIMODA IGAWA Y, Yoshida T, Makihara R, Torasawa M, et al
Association between lorlatinib blood concentration and adverse events and clinical impact of dose modification.
Lung Cancer. 2024;196:107954.
PubMed Abstract available

WATERHOUSE DM, Rothschild S, Dooms C, Mennecier B, et al
Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation.
Lung Cancer. 2024;196:107921.
PubMed Abstract available

ZHU C
What's behind thoracic surgery explosion in young patients under the age of 40 in Wuhan after COVID-19 outbreak?
Lung Cancer. 2024;196:107937.
PubMed Abstract available

YANG G, Chu Q
Comment on: Effects of pregabalin combined with tramadol/paracetamol on acute pain in patients with CT-guided puncture localization of pulmonary nodules.
Lung Cancer. 2024;196:107938.
PubMed

September 2024

OU SH, Kilvert H, Candlish J, Lee B, et al
Systematic review and network meta-analysis of lorlatinib with comparison to other anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) as first-line treatment for ALK-positive advanced non-smallcell lung cancer (NSCLC).
Lung Cancer. 2024;197:107968.
PubMed Abstract available

CHEN R, Donlon TA, Morris BJ, Allsopp RC, et al
Association of alcohol with lung cancer risk in men with different growth hormone receptor genotypes.
Lung Cancer. 2024;198:107971.
PubMed Abstract available

KANG DW, Park SK, Kang S, Lee EK, et al
Cost-effectiveness of next-generation sequencing for advanced EGFR/ALK-negative non-small cell lung cancer.
Lung Cancer. 2024;197:107970.
PubMed Abstract available

PLANCHARD D, Wolf J, Solomon B, Sebastian M, et al
A phase Ib study of the combination of naporafenib with rineterkib or trametinib in patients with advanced and metastatic KRAS- or BRAF-mutant non-small cell lung cancer.
Lung Cancer. 2024;197:107964.
PubMed Abstract available

KAWAGUCHI K, Ogura T, Kaneda S, Watanabe T, et al
A prospective multi-institutional study to verify the non-inferiority of postoperative pain in robot-assisted thoracic surgery in comparison with video-assisted thoracoscopic surgery for lung cancer: The Japanese RATS interest group 01 (J-RATSIG 01).
Lung Cancer. 2024;196:107961.
PubMed Abstract available

LI L, Liu N, Zhou T, Qin X, et al
A biomarker exploration in small-cell lung cancer for brain metastases risk and prophylactic cranial irradiation therapy efficacy.
Lung Cancer. 2024;196:107959.
PubMed Abstract available

SHIBAKI R, Fujimoto D, Miyauchi E, Tsukita Y, et al
Durvalumab with etoposide and carboplatin for patients with extensive-stage small cell lung cancer and interstitial lung disease: A multicenter, open-label prospective trial.
Lung Cancer. 2024;196:107958.
PubMed Abstract available

JOHNSON M, Younan D, Kent ST, Mesa-Frias M, et al
Real-world comparative effectiveness of sotorasib versus docetaxel in second line and beyond among patients with advanced non-small cell lung cancer (NSCLC).
Lung Cancer. 2024;197:107960.
PubMed Abstract available

ZHENG MZ, Yang ZQ, Cai SL, Zheng LT, et al
Blood-brain barrier and blood-brain tumor barrier penetrating peptide-drug conjugate as targeted therapy for the treatment of lung cancer brain metastasis.
Lung Cancer. 2024;196:107957.
PubMed Abstract available

MARSHALL HM, Fong KM
Lung cancer screening - Time for an update?
Lung Cancer. 2024;196:107956.
PubMed Abstract available

MILDNER FO, Sykora MM, Hackl H, Amann A, et al
Soluble PD-L1 shows no association to relapse and overall survival in early stage non-small cell lung cancer (NSCLC).
Lung Cancer. 2024;196:107955.
PubMed Abstract available

PRESLEY CJ, Tang J, Benedict J, Grogan M, et al
Functional resilience and overall survival in adults treated for advanced non-small-cell lung cancer.
Lung Cancer. 2024;196:107953.
PubMed Abstract available

MARKS JA, Gandhi N, Halmos B, Marmarelis ME, et al
Molecular profiling METex14+ non-small cell lung cancer (NSCLC): Impact of histology.
Lung Cancer. 2024;196:107935.
PubMed Abstract available

PEETERS S, Lau K, Stefanidis K, Yasufuku K, et al
New diagnostic and nonsurgical local treatment modalities for early stage lung cancer.
Lung Cancer. 2024;196:107952.
PubMed Abstract available

MANSFIELD AS, Vivien Yin J, Bradbury P, Kwiatkowski DJ, et al
Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma.
Lung Cancer. 2024;195:107928.
PubMed Abstract available

LIU KJ, Li HR, Tan QQ, Jiang T, et al
Tumor immune microenvironment of NSCLC with EGFR exon 20 insertions may predict efficacy of first-line ICI-combined regimen.
Lung Cancer. 2024;195:107933.
PubMed Abstract available

NASO J, Desai A, Smith CJ, Ashara YP, et al
Predictive value and molecular correlates of MYC immunohistochemistry and copy number gain in non-small cell lung carcinomas treated with immunotherapy.
Lung Cancer. 2024;195:107927.
PubMed Abstract available

WEI Y, Wu R, Yang S, Cao Y, et al
MiR-137 mediated high expression of TIGD1 promotes migration, invasion, and suppresses apoptosis of lung adenocarcinoma.
Lung Cancer. 2024;195:107918.
PubMed Abstract available

LI Y, Xie F, Zheng Q, Zhang Y, et al
Non-invasive diagnosis of pulmonary nodules by circulating tumor DNA methylation: A prospective multicenter study.
Lung Cancer. 2024;195:107930.
PubMed Abstract available

YING L, Lu T, Tian Y, Guo H, et al
A predictive model for prognostic risk stratification of early-stage NSCLC based on clinicopathological and miRNA panel.
Lung Cancer. 2024;195:107902.
PubMed Abstract available

ALIREZAIE N, Chong AL, Kommoss FKF, Sabbaghian N, et al
Exomic and epigenomic analysis of pulmonary blastoma.
Lung Cancer. 2024;195:107916.
PubMed Abstract available

OTTE N, Fraune E, Cetiner Y, Felten MK, et al
Asbestos Surveillance Program Aachen (ASPA): Cancer mortality among asbestos exposed power industry workers.
Lung Cancer. 2024;195:107899.
PubMed Abstract available

LU S, Zhang Y, Zhang G, Zhou J, et al
Befotertinib for patients with pretreated EGFR T790M mutated locally advanced or metastatic NSCLC: Final overall survival results from a phase 2 trial.
Lung Cancer. 2024;195:107901.
PubMed Abstract available

August 2024

GRIT GF, van Geffen E, Malmberg R, van Leeuwen R, et al
Real-world overall survival after alternative dosing for pembrolizumab in the treatment of non-small cell lung cancer: A nationwide retrospective cohort study with a non-inferiority primary objective.
Lung Cancer. 2024;196:107950.
PubMed Abstract available

LIAO D, Long M, Zhang J, Wei X, et al
Efficacy and safety of pralsetinib in patients with RET fusion positive non-small cell lung cancer: An observational real world study.
Lung Cancer. 2024;196:107936.
PubMed Abstract available

FERREIRA M, Swalduz A, Greillier L, du Rusquec P, et al
Capmatinib efficacy for METex14 non-small cell lung cancer patients: Results of the IFCT-2104 CAPMATU study.
Lung Cancer. 2024;196:107934.
PubMed Abstract available

MALHOTRA J, Chiappori A, Fujioka N, Hanna NH, et al
Phase I/II trial of plinabulin in combination with nivolumab and ipilimumab in patients with recurrent small cell lung cancer (SCLC): Big ten cancer research consortium (BTCRC-LUN17-127) study.
Lung Cancer. 2024;195:107932.
PubMed Abstract available

TASOUDIS P, Loufopoulos G, Manaki V, Doerr M, et al
Long term outcomes after lobar versus sublobar resection for patients with Non-Small cell lung Cancer: Systematic review and individual patient data Meta-Analysis.
Lung Cancer. 2024;195:107929.
PubMed Abstract available

BARSOUK A, Elghawy O, Heidlauf A, Yu C, et al
Real-world outcomes of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC)treated with osimertinib (osi) vs. Afatinib or erlotinib.
Lung Cancer. 2024;195:107926.
PubMed Abstract available

RECK M, Dziadziuszko R, Sugawara S, Kao S, et al
Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension study.
Lung Cancer. 2024;196:107924.
PubMed Abstract available

CALVO V, Niazmand E, Carcereny E, Rodriguez-Abreu D, et al
Family history of cancer and lung cancer: Utility of big data and artificial intelligence for exploring the role of genetic risk.
Lung Cancer. 2024;195:107920.
PubMed Abstract available

DING Y, Lei S, Wang L, Tang L, et al
Age-related efficacy of immunotherapies in advanced non-small cell lung cancer: a comprehensive meta-analysis.
Lung Cancer. 2024;195:107925.
PubMed Abstract available

TAMIYA A, Osuga M, Harada D, Isa SI, et al
Mechanisms of resistance and correlation between pre-treatment co-alterations and p-prognosis to osimertinib in chemo-naive advanced non-small cell lung cancer.
Lung Cancer. 2024;195:107917.
PubMed Abstract available

BAUMAN JR, Liu G, Preeshagul I, Liu SV, et al
Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer.
Lung Cancer. 2024;195:107919.
PubMed Abstract available

GALLINA FT, Balzano V, Porciello N, Taje R, et al
Trajectory of PD-L1 expression in a patient underwent neoadjuvant chemo-immunotherapy for resectable NSCLC.
Lung Cancer. 2024;194:107900.
PubMed

BARGHOUT SH, Zhan LJ, Raptis S, Al-Agha F, et al
Treatment patterns and outcomes in KRAS(G12C)-positive advanced NSCLC patients previously treated with immune checkpoint inhibitors: A Canada-wide real-world, multi-center, retrospective cohort study.
Lung Cancer. 2024;194:107898.
PubMed Abstract available

OYA Y, Imaizumi K, Mitsudomi T
The next-generation KRAS inhibitors...What comes after sotorasib and adagrasib?
Lung Cancer. 2024;194:107886.
PubMed Abstract available

WESPISER M, Swalduz A, Perol M
Treatment sequences in EGFR mutant advanced NSCLC.
Lung Cancer. 2024;194:107895.
PubMed Abstract available

WANG Q, Liu H, Xu Z, Zhang L, et al
Effects of pregabalin combined with tramadol/paracetamol on acute pain in patients with CT-guided puncture localization of pulmonary nodules.
Lung Cancer. 2024;194:107888.
PubMed Abstract available

HUANG S, Cao C, Guo L, Li C, et al
Comparison of the variability and diagnostic efficacy of respiratory-gated PET/CT based radiomics features with ungated PET/CT in lung lesions.
Lung Cancer. 2024;194:107889.
PubMed Abstract available

DOUMA LH, Baas P, de Gooijer CJ
First-line doublet immunotherapy: Game changer or hype for patients with mesothelioma?
Lung Cancer. 2024;194:107891.
PubMed

XU Y, Zhang Y, Qiang H, Zhong H, et al
Impact of PD-L1 expression on the efficacy of first-line crizotinib in advanced ROS1-rearranged NSCLC.
Lung Cancer. 2024;194:107892.
PubMed Abstract available

NIEDERMAIER B, Kou Y, Tong E, Eichinger M, et al
CT-guided needle biopsy is not associated with increased ipsilateral pleural metastasis.
Lung Cancer. 2024;194:107890.
PubMed Abstract available

SPEEL EM, Dafni U, Thunnissen E, Hendrik Ruschoff J, et al
ROS1 fusions in resected stage I-III adenocarcinoma: Results from the European Thoracic Oncology Platform Lungscape project.
Lung Cancer. 2024;194:107860.
PubMed Abstract available

KIM YJ, Kim S, Kim TM, Suh KJ, et al
A phase II study of osimertinib in patients with NSCLC harboring EGFR exon 20 insertion: A multicenter trial of the Korean Cancer Study Group (LU17-19).
Lung Cancer. 2024;194:107870.
PubMed Abstract available

BYLICKI O, Guisier F, Scherpereel A, Daniel C, et al
Real-World efficacy and safety of combination nivolumab plus ipilimumab for Untreated, Unresectable, pleural Mesothelioma: The Meso-Immune (GFPC 04-2021) trial.
Lung Cancer. 2024;194:107866.
PubMed Abstract available

OGAWA H, Koga T, Pham NA, Bernards N, et al
Clinical and pathological predictors of engraftment for patient-derived xenografts in lung adenocarcinoma.
Lung Cancer. 2024;194:107863.
PubMed Abstract available

PROVENCIO M, Robado de Lope L, Serna-Blasco R, Nadal E, et al
BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC.
Lung Cancer. 2024;194:107865.
PubMed Abstract available

ARRIETA O, Caballe-Perez E, Hernandez-Pedro N, Romero-Nunez E, et al
Prevalence of pathogenic or likely pathogenic germline variants in cancer predisposition genes among selected patients with lung adenocarcinoma: The GERMLUNG study.
Lung Cancer. 2024;194:107864.
PubMed Abstract available

July 2024

CASIRAGHI M, Cara A, Mazzella A, Girelli L, et al
1000 Robotic-assisted lobectomies for primary lung cancer: 16 years single center experience.
Lung Cancer. 2024;195:107903.
PubMed Abstract available

ZHENG Q, Lin X, Qi W, Yin J, et al
NGS and FISH for MET amplification detection in EGFR TKI resistant non-small cell lung cancer (NSCLC) patients: A prospective, multicenter study in China.
Lung Cancer. 2024;194:107897.
PubMed Abstract available

FUJIMOTO D, Hayashi H, Murotani K, Toi Y, et al
Prediction of prognosis in lung cancer using machine learning with inter-institutional generalizability: A multicenter cohort study (WJOG15121L: REAL-WIND).
Lung Cancer. 2024;194:107896.
PubMed Abstract available

ASAO T, Shukuya T, Uemura K, Kitadai R, et al
Risk and survival of patients with non-small cell lung cancer and pre-existing autoimmune disorders receiving immune checkpoint blockade therapy: Survival analysis with inverse probability weighting from a nationwide, multi-institutional, retrospectiv
Lung Cancer. 2024;194:107894.
PubMed Abstract available

BELLUOMINI L, Cesta Incani U, Smimmo A, Avancini A, et al
Prognostic impact of Interleukin-8 levels in lung cancer: A meta-analysis and a bioinformatic validation.
Lung Cancer. 2024;194:107893.
PubMed Abstract available

JACOB M, Fournel P, Tissot C, Cadranel J, et al
A prospective analysis of the management practices for patients with Stage-III-N2Non-Small-Cell lung cancer (OBSERVE IIIA-B GFPC 04-2020Study).
Lung Cancer. 2024;194:107868.
PubMed Abstract available

ZANDWIJK NV, Frank AL, Reid G, Dimitri Roe O, et al
Asbestos-Related lung Cancer: An underappreciated oncological issue.
Lung Cancer. 2024;194:107861.
PubMed Abstract available

PONS-TOSTIVINT E, Ezzedine R, Goronflot T, Crequit P, et al
Second-line treatment outcomes after first-line chemotherapy plus immunotherapy in Extensive-Stage small cell lung cancer (ES-SCLC) patients: A large French multicenter study.
Lung Cancer. 2024;194:107887.
PubMed Abstract available

IZUMI M, Costa DB, Kobayashi SS
Targeting of drug-tolerant persister cells as an approach to counter drug resistance in non-small cell lung cancer.
Lung Cancer. 2024;194:107885.
PubMed Abstract available

LI R, Xu Y, Zhao J, Zhang L, et al
Comparison of radiotherapy versus surgical resection following neoadjuvant chemoimmunotherapy in potentially resectable stage III non-small-cell lung cancer: A propensity score matching analysis.
Lung Cancer. 2024;194:107884.
PubMed Abstract available

YOSHIZAKI C, Yoshida Y, Nohmi S, Go Y, et al
EGFR-TKI-induced Factor V deficiency in a patient with advanced non-small cell lung cancer: The first case report.
Lung Cancer. 2024;194:107869.
PubMed Abstract available

DE BRUYCKER A, Schneiders F, Gulstene S, Moghanaki D, et al
Evaluation of chest CT-scans following lung stereotactic ablative radiotherapy: Challenges and new insights.
Lung Cancer. 2024;193:107848.
PubMed Abstract available

SAW SPL, Low YF, Lai GGY, Chan LL, et al
Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLC.
Lung Cancer. 2024;193:107856.
PubMed Abstract available

ARMATO SG 3RD, Katz SI, Frauenfelder T, Jayasekera G, et al
Imaging in pleural Mesothelioma: A review of the 16th International Conference of the International Mesothelioma Interest Group.
Lung Cancer. 2024;193:107832.
PubMed Abstract available

BORGHAEI H, Pundole X, Sangare L, Anderson E, et al
Natural history of SCLC patients treated in third-line and beyond: A retrospective real world study.
Lung Cancer. 2024;193:107819.
PubMed Abstract available

FRANK AL, van Zandwijk N
Asbestos history and use.
Lung Cancer. 2024;193:107828.
PubMed Abstract available

ERNST SM, van Marion R, von der Thusen JH, Dubbink HJ, et al
Exploring the use of circulating tumor DNA for mutational signature analysis.
Lung Cancer. 2024;193:107844.
PubMed

June 2024

BLANCO-VILLAR ML, Exposito-Hernandez J, Navarro-Moreno E, Lopez Martin JM, et al
Analyzing diagnostic and treatment wait times for lung cancer Patients: Key insights from a provincial registry study.
Lung Cancer. 2024;194:107867.
PubMed Abstract available

NISHIO M, Watanabe S, Udagawa H, Aragane N, et al
Integrated analysis of older adults and patients with renal dysfunction in the IMpower130 and IMpower132 randomized controlled trials for advanced non-squamous non-small cell lung cancer.
Lung Cancer. 2024 Jun 28:107859. doi: 10.1016/j.lungcan.2024.107859.
PubMed Abstract available

BUM LEE J, Huang Y, Oya Y, Nutzinger J, et al
Modulating the gut microbiome in non-small cell lung cancer: Challenges and opportunities.
Lung Cancer. 2024;194:107862.
PubMed Abstract available

BEN-ARYE E, Gressel O, Lifshitz S, Peled N, et al
Integrative oncology for patients with lung cancer: A prospective pragmatic controlled trial.
Lung Cancer. 2024;193:107857.
PubMed Abstract available

KLEBE S, Rathi V, Russell PA
Lung cancer caused by asbestos: What a reporting pathologist needs to know.
Lung Cancer. 2024;195:107849.
PubMed Abstract available

METINTAS M, Ak G, Metintas S
Environmental asbestos exposure and lung cancer.
Lung Cancer. 2024;194:107850.
PubMed Abstract available

ASANO Y, Yamamoto N, Demura S, Hayashi K, et al
Combination therapy with immune checkpoint inhibitors and denosumab improves clinical outcomes in non-small cell lung cancer with bone metastases.
Lung Cancer. 2024;193:107858.
PubMed Abstract available

TAKEDA M, Shimokawa M, Nakamura A, Nosaki K, et al
Corrigendum to "A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKI and platin
Lung Cancer. 2024 Jun 17:107852. doi: 10.1016/j.lungcan.2024.107852.
PubMed

CUPPENS K, Du Pont B, Knegjens J, Maes B, et al
Immune checkpoint inhibition in early-stage non-small cell lung cancer.
Lung Cancer. 2024;193:107855.
PubMed Abstract available

APTEKAR J, Jain R, Korytowsky B, Shafquat A, et al
Brain metastases in clinical trial participants with KRAS-mutated advanced non-small cell lung cancer receiving docetaxel: Pooled data analysis.
Lung Cancer. 2024;193:107854.
PubMed Abstract available

ARRIETA O
In response to "On the Hispanic paradox in lung cancer".
Lung Cancer. 2024;193:107853.
PubMed

GAO X, Tan H, Zhu M, Zhang G, et al
Construction and validation of a clinical differentiation model between peripheral lung cancer and solitary pulmonary tuberculosis.
Lung Cancer. 2024;193:107851.
PubMed Abstract available

MAHMOOD K, Wang H, Ji Z, Giovacchini CX, et al
Differences in microenvironment of lung cancer and pleural effusions by single-cell RNA sequencing.
Lung Cancer. 2024;193:107847.
PubMed Abstract available

HUANG L, Petersen RH
Impact of number of dissected lymph nodes on recurrence and survival following thoracoscopic segmentectomy for clinical stage I non-small cell lung cancer.
Lung Cancer. 2024;193:107846.
PubMed Abstract available

GOTO E, Taki T, Nomura K, Miyakami Y, et al
Clinicopathological differences between EGFR mutated and EGFR wild-type lung adenocarcinoma with papillary predominant pattern.
Lung Cancer. 2024;192:107830.
PubMed Abstract available

LI M, Zhang Y, Zhou P, Miao Y, et al
Mutational analysis of pulmonary large cell neuroendocrine carcinoma: APC gene mutations identify a good prognostic factor.
Lung Cancer. 2024;192:107825.
PubMed Abstract available

VORUGANTI MADDALI IS, Cunningham C, McLeod L, Bahig H, et al
Optimal management of radiation pneumonitis: Findings of an international Delphi consensus study.
Lung Cancer. 2024;192:107822.
PubMed Abstract available

SHI M, Pang L, Zhou H, Mo S, et al
Rare SMARCA4-deficient thoracic tumor: Insights into molecular characterization and optimal therapeutics methods.
Lung Cancer. 2024;192:107818.
PubMed Abstract available

SZENTKERESZTY M, Ladanyi A, Galffy G, Tovari J, et al
Density of tumor-infiltrating NK and Treg cells is associated with 5 years progression-free and overall survival in resected lung adenocarcinoma.
Lung Cancer. 2024;192:107824.
PubMed Abstract available

CHEN Q, Xia L, Wang J, Zhu S, et al
EGFR-mutant NSCLC may remodel TME from non-inflamed to inflamed through acquiring resistance to EGFR-TKI treatment.
Lung Cancer. 2024;192:107815.
PubMed Abstract available

SHAH R, Sun L, Ridge CA
Image guided lung biopsy.
Lung Cancer. 2024;192:107803.
PubMed Abstract available

MARTIN A, Carton M, Thery L, Burnod A, et al
Palliative care integration and end-of-life care intensity for patients with NSCLC.
Lung Cancer. 2024;192:107800.
PubMed Abstract available

ISHIDOYA M, Makiguchi T, Tanaka H, Miura T, et al
Endocrine immune-related adverse event is a prognostic biomarker independent of lead-time bias.
Lung Cancer. 2024;192:107790.
PubMed Abstract available

KLOTZ LV, Casjens S, Johnen G, Taeger D, et al
Combination of calretinin, MALAT1, and GAS5 as a potential prognostic biomarker to predict disease progression in surgically treated mesothelioma patients.
Lung Cancer. 2024;192:107802.
PubMed Abstract available

May 2024

AMARI L, Tomasini P, Dantony E, Rousseau-Bussac G, et al
Safety and Patient-Reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab in stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies (GFPC
Lung Cancer. 2024;193:107843.
PubMed Abstract available

PENG L, Lidan H, Cuicui Z, Zhe Z, et al
DNA double-strand break repair capacity and its pathway gene variants predict the risk and prognosis of lung cancer.
Lung Cancer. 2024;192:107831.
PubMed Abstract available

KE H, Kao S, van Zandwijk N, Rasko JEJ, et al
Circulating tumor cell detection may offer earlier diagnosis in patients suspected of asbestos-related lung cancer.
Lung Cancer. 2024;192:107829.
PubMed Abstract available

LUNDBERG FE, Ekman S, Johansson ALV, Engholm G, et al
Trends in lung cancer survival in the Nordic countries 1990-2016: The NORDCAN survival studies.
Lung Cancer. 2024;192:107826.
PubMed Abstract available

HUANG Z, Zhang Y, Xu Q, Song L, et al
Clinical treatment patterns, molecular characteristics and survival outcomes of ROS1-rearranged non-small cell lung cancer: A large multicenter retrospective study.
Lung Cancer. 2024;192:107827.
PubMed Abstract available

LI Y, Wong M, Zhan L, Corke L, et al
Single organ metastatic sites in non-small cell lung cancer: Patient characteristics, treatment patterns and outcomes from a large retrospective Canadian cohort.
Lung Cancer. 2024;192:107823.
PubMed Abstract available

BARAMIDZE A, Makharadze T, Gogishvili M, Melkadze T, et al
Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer with PD-L1 >/= 1 %: A subgroup analysis from the EMPOWER-Lung 3 part 2 trial.
Lung Cancer. 2024;193:107821.
PubMed Abstract available

FELIP E, Metro G, Tan DSW, Wolf J, et al
Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non-small cell lung cancer.
Lung Cancer. 2024;192:107820.
PubMed Abstract available

NADAL E, Rifi N, Kane S, Mbacke S, et al
Efficacy and safety of crizotinib in the treatment of advanced non-small cell lung cancer with ROS1 gene fusion: a systematic literature review and meta-analysis of real-world evidence.
Lung Cancer. 2024;192:107816.
PubMed Abstract available

WANG Z, Li X, Chen J, Hua Y, et al
The significance of inflammatory markers in prognosticating the effectiveness and safety of immunotherapy in conjunction with chemotherapy during the primary intervention of advanced non-small cell lung carcinoma.
Lung Cancer. 2024;192:107817.
PubMed Abstract available

WANG L, Li L, Zhou X, Zhang D, et al
Identification of a novel ALK inhibitor-sensitive PRKCE-ALK gene fusion in lung adenocarcinoma.
Lung Cancer. 2024;191:107797.
PubMed

LU YF, Chang YH, Chen YJ, Hsieh MS, et al
Proteomic profiling of tumor microenvironment and prognosis risk prediction in stage I lung adenocarcinoma.
Lung Cancer. 2024;191:107791.
PubMed Abstract available

CHOUR A, Basse C, Lebosse F, Bonte PE, et al
Management of sotorasib-related adverse events and hepatotoxicities following anti-PD-(L)1 therapy: Experience with sotorasib in two French anti-cancer centers and practical guidance proposal.
Lung Cancer. 2024;191:107789.
PubMed Abstract available

MIYAKOSHI J, Yoshida T, Kashima J, Shirasawa M, et al
Clinical significance of inter-assay discrepancy in PD-L1 evaluation for the efficacy of pembrolizumab in advanced NSCLC with high PD-L1 expression.
Lung Cancer. 2024;191:107788.
PubMed Abstract available

NISHIMURA T, Fujimoto H
Is the onset of immune-related adverse events themselves a prognostic factor or a confounding factor?
Lung Cancer. 2024;191:107561.
PubMed

HOCKING AJ, Mortimer LA, Farrall AL, Russell PA, et al
Establishing mesothelioma patient-derived organoid models from malignant pleural effusions.
Lung Cancer. 2024;191:107542.
PubMed Abstract available

LIU G, Mazieres J, Stratmann J, Ou SI, et al
A pragmatic guide for management of adverse events associated with lorlatinib.
Lung Cancer. 2024;191:107535.
PubMed Abstract available

April 2024

OKAHISA M, Udagawa H, Matsumoto S, Kato T, et al
Clinical outcomes in patients with non-small cell lung cancer harboring EGFR Exon20 in-frame insertions in the near-loop and far-loop: Results from LC-SCRUM-Asia.
Lung Cancer. 2024;191:107798.
PubMed Abstract available

ZHANG SL, Tian Y, Yu J, Zhang JH, et al
Is neoadjuvant immunotherapy necessary in patients with programmed death ligand 1 expression-negative resectable non-small cell lung cancer? A systematic review and meta-analysis.
Lung Cancer. 2024;191:107799.
PubMed Abstract available

BADE BC, Zhao J, Li F, Tanoue L, et al
Trends and predictors of Quality of Life in lung cancer survivors.
Lung Cancer. 2024;191:107793.
PubMed Abstract available

LIU S, Graves N, Tan AC
The cost-effectiveness of including liquid biopsy into molecular profiling strategies for newly diagnosed advanced non-squamous non-small cell lung cancer in an Asian population.
Lung Cancer. 2024;191:107794.
PubMed Abstract available

DE RUITER JC, van der Noort V, van Diessen JNA, Smit EF, et al
The optimal treatment for patients with stage I non-small cell lung cancer: minimally invasive lobectomy versus stereotactic ablative radiotherapy - a nationwide cohort study.
Lung Cancer. 2024;191:107792.
PubMed Abstract available

MALAPELLE U, Passiglia F, Pepe F, Pisapia P, et al
The biomarkers ATLAS: An audit on 1100 non-small cell lung cancer from an Italian knowledge-based database.
Lung Cancer. 2024;191:107787.
PubMed Abstract available

TAVERNA JA, Hung CN, Williams M, Williams R, et al
Ex vivo drug testing of patient-derived lung organoids to predict treatment responses for personalized medicine.
Lung Cancer. 2024;190:107533.
PubMed Abstract available

JUNG HA, Park B, Park S, Sun JM, et al
Survival benefit in EGFR-wild and ALK negative NSCLC patients who participate in clinical trials compared to standard-of-care: Propensity-matched analysis.
Lung Cancer. 2024;190:107536.
PubMed Abstract available

YU T, Zhou X, Li M
Comment on: Frozen sections accurately predict the IASLC proposed grading system and prognosis in patients with invasive lung adenocarcinomas.
Lung Cancer. 2024;190:107534.
PubMed

PANG LL, Zhuang WT, Huang YH, Liao J, et al
Uncommon de novo EGFR(T790M)-Mutant NSCLC characterized with unique genetic Features: Clinical response and acquired resistance to the third-generation EGFR-TKIs treatment.
Lung Cancer. 2024;190:107528.
PubMed Abstract available

DAMHUIS RAM, Dickhoff C, Bahce I, Senan S, et al
Population-based survival rates after curative surgical and non-surgical treatment of stage III NSCLC since 2017.
Lung Cancer. 2024;190:107532.
PubMed Abstract available

SLATORE CG, Hooker ER, Shull S, Golden SE, et al
Association of patient and health care organization factors with incidental nodule guidelines adherence: A multi-system observational study.
Lung Cancer. 2024;190:107526.
PubMed Abstract available

SUN L, Handorf EA, Zhou Y, Borghaei H, et al
Outcomes in patients treated with frontline immune checkpoint inhibition (ICI) for advanced NSCLC with KRAS mutations and STK11/KEAP1 comutations across PD-L1 levels.
Lung Cancer. 2024;190:107510.
PubMed Abstract available

PROVENCIO M, Cobo M, Rodriguez-Abreu D, Carcereny E, et al
Describing differences among populations of thoracic tumors patients under and over 80 years: Data analysis from the SLCG thoracic tumor registry.
Lung Cancer. 2024;190:107513.
PubMed Abstract available

HONG DS, Cappuzzo F, Chul Cho B, Dowlati A, et al
Phase II study investigating the efficacy and safety of glesatinib (MGCD265) in patients with advanced NSCLC containing MET activating alterations.
Lung Cancer. 2024;190:107512.
PubMed Abstract available

March 2024

GABRIEL L, McVeigh T, Macmahon S, Avila Z, et al
Familial rare EGFR-mutant lung cancer syndrome: Review of literature and description of R776H family.
Lung Cancer. 2024;191:107543.
PubMed Abstract available

LYHNE CHRISTENSEN N, Gouliaev A, McPhail S, Lyratzopoulos G, et al
Lung cancer among the Elderly in Denmark - A comprehensive population-based cohort study.
Lung Cancer. 2024;191:107555.
PubMed Abstract available

SUN M, Feng Q, Yan Q, Zhao H, et al
Malate, a natural inhibitor of 6PGD, improves the efficacy of chemotherapy in lung cancer.
Lung Cancer. 2024;190:107541.
PubMed Abstract available

TOZUKA T, Noro R, Mizutani H, Kurimoto F, et al
Osimertinib plus local treatment for brain metastases versus osimertinib alone in patients with EGFR-Mutant Non-Small Cell Lung Cancer.
Lung Cancer. 2024;191:107540.
PubMed Abstract available

RODRIGUEZ J
On the Hispanic paradox in lung cancer.
Lung Cancer. 2024;190:107537.
PubMed

GUDINA AT, Kamen C, Hardy SJ, Kehoe L, et al
Revisiting the lung cancer screening eligibility criteria to promote equity for Black individuals.
Lung Cancer. 2024;191:107539.
PubMed Abstract available

PU X, Xiao Z, Li J, Wu Z, et al
Anlotinib plus docetaxel vs. docetaxel alone for advanced non-small-cell lung cancer patients who failed first-line treatment: A multicenter, randomized phase II trial.
Lung Cancer. 2024;191:107538.
PubMed Abstract available

WALLACE ND, Alexander M, Xie J, Ball D, et al
The impact of pre-treatment smoking status on survival after chemoradiotherapy for locally advanced non-small-cell lung cancer.
Lung Cancer. 2024;190:107531.
PubMed Abstract available

KIM DW, Chul Cho B, Pachipala K, Kim SW, et al
Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III non-small-cell lung cancer: Results from the phase 1 CLOVER study.
Lung Cancer. 2024;190:107530.
PubMed Abstract available

CONNOR WELLS J, Mullin MM, Ho C, Melosky B, et al
Outcomes of patients with advanced epithelial growth factor receptor mutant lung cancer treated with first-line osimertinib who would not have met the eligibility criteria for the FLAURA clinical trial.
Lung Cancer. 2024;190:107529.
PubMed Abstract available

KRAUS KM, Oreshko M, Schnabel JA, Bernhardt D, et al
Dosiomics and radiomics-based prediction of pneumonitis after radiotherapy and immune checkpoint inhibition: The relevance of fractionation.
Lung Cancer. 2024;189:107507.
PubMed Abstract available

KAIRA K, Imai H, Kagamu H
Drastic response of sunitinib after failure of Lenvatinib in patients with previously treated thymic carcinoma.
Lung Cancer. 2024;189:107501.
PubMed

ZHOU P, Fu Y, Tang Y, Jiang L, et al
Thoracic SMARCA4-deficient undifferentiated tumor: A clinicopathological and prognostic analysis of 35 cases and immunotherapy efficacy.
Lung Cancer. 2024;189:107471.
PubMed Abstract available

MOLINA TJ, Roden AC, Szolkowska M, Shimizu S, et al
International reproducibility study of thymic epithelial tumors staging: pT stage is an issue. proposals for improvement. A RYTHMIC/ITMIG study.
Lung Cancer. 2024;189:107479.
PubMed Abstract available

KLOKER LD, Sidiras M, Flaadt T, Brecht IB, et al
Clinical management of NUT carcinoma (NC) in Germany: Analysis of survival, therapy response, tumor markers and tumor genome sequencing in 35 adult patients.
Lung Cancer. 2024;189:107496.
PubMed Abstract available

FITZGERALD SM
Resolving asbestos and ultrafine particulate definitions with carcinogenicity.
Lung Cancer. 2024;189:107478.
PubMed Abstract available

STARES M, Doyle E, Chapple S, Raynes G, et al
Prognostic value of the Scottish Inflammatory prognostic Score in patients with NSCLC expressing PD-L1 >/= 50 % progressing on first-line pembrolizumab.
Lung Cancer. 2024;189:107497.
PubMed Abstract available

CHEN Y, Chen H, Yu R, Zeng X, et al
Pulmonary blastoma is successfully treated with immunotherapy and targeted therapy.
Lung Cancer. 2024;189:107476.
PubMed Abstract available

February 2024

GOULIAEV A, Ali F, Jakobsen E, Dalton SO, et al
The Danish lung cancer registry: A nationwide validation study.
Lung Cancer. 2024;190:107527.
PubMed Abstract available

LEE JD, Zheng R, Okusanya OT, Evans NR 3rd, et al
Association between surgical quality and long-term survival in lung cancer.
Lung Cancer. 2024;190:107511.
PubMed Abstract available

SAEKI Y, Maki N, Nemoto T, Inada K, et al
Lung cancer detection in perioperative patients' exhaled breath with nanomechanical sensor array.
Lung Cancer. 2024;190:107514.
PubMed Abstract available

CHUL CHO B, Han JY, Hyeong Lee K, Lee YG, et al
Lazertinib as a frontline treatment in patients with EGFR-mutated advanced non-small cell lung cancer: Long-term follow-up results from LASER201.
Lung Cancer. 2024;190:107509.
PubMed Abstract available

BAPTISTE OUDART J, Garinet S, Leger C, Barlesi F, et al
STK11/LKB1 alterations worsen the poor prognosis of KRAS mutated early-stage non-squamous non-small cell lung carcinoma, results based on the phase 2 IFCT TASTE trial.
Lung Cancer. 2024;190:107508.
PubMed Abstract available

BAR J, Esteban E, Rodriguez-Abreu D, Aix SP, et al
Blood tumor mutational burden and response to pembrolizumab plus chemotherapy in non-small cell lung cancer: KEYNOTE-782.
Lung Cancer. 2024;190:107506.
PubMed Abstract available

SAAL J, Bald T, Eckstein M, Ralser DJ, et al
Integration of on-treatment modified Glasgow prognostic score (mGPS) to improve imaging-based prediction of outcomes in patients with non-small cell lung cancer on immune checkpoint inhibition.
Lung Cancer. 2024;189:107505.
PubMed Abstract available

LAESEKE P, Ng C, Naghi A, Wright GWJ, et al
Response to letter: Microwave ablation for Early-Stage Non-Small cell Lung Cancer: Don't Put the Cart before the stereotactic Horse.
Lung Cancer. 2024;189:107504.
PubMed

WANG S, Hao X, Dai L, Lou N, et al
Longitudinal plasma proteomic profiling of EML4-ALK positive lung cancer receiving ALK-TKIs therapy.
Lung Cancer. 2024;189:107503.
PubMed Abstract available

SAIGI M, Mate JL, Carcereny E, Martinez-Cardus A, et al
HLA-I levels correlate with survival outcomes in response to immune checkpoint inhibitors in non-small cell lung cancer.
Lung Cancer. 2024;189:107502.
PubMed Abstract available

KUNIMASA K, Tamiya M, Inoue T, Kawamura T, et al
Clinical application of the Lung Cancer Compact Panel(TM) using various types of cytological specimens in patients with lung cancer.
Lung Cancer. 2024;189:107498.
PubMed Abstract available

LIU SV, Frohn C, Minasi L, Fernamberg K, et al
Real-world outcomes associated with afatinib use in patients with solid tumors harboring NRG1 gene fusions.
Lung Cancer. 2024;188:107469.
PubMed Abstract available

ZHANG YH, Liu XS, Gao Y, Yuan LL, et al
SFXN1 as a potential diagnostic and prognostic biomarker of LUAD is associated with (18)F-FDG metabolic parameters.
Lung Cancer. 2024;188:107449.
PubMed Abstract available

KITAGAWA S, Zenke Y, Taki T, Aokage K, et al
Prognostic value of predominant subtype in pathological stage II-III lung adenocarcinoma with epidermal growth factor receptor mutation.
Lung Cancer. 2024;188:107453.
PubMed Abstract available

BURNS L, Tukachinsky H, Raskina K, Huang RSP, et al
Real-World comprehensive genomic profiling data for diagnostic clarity in pulmonary Large-Cell neuroendocrine carcinoma.
Lung Cancer. 2024;188:107454.
PubMed Abstract available

January 2024

WANG Y, Hu C, Yu H, Hu J, et al
Insensitivity of oncogenic EGFR R776L mutation to EGFR inhibitors in lung cancer.
Lung Cancer. 2024;189:107495.
PubMed Abstract available

HUANG S, Zhao M, Li S, Chen T, et al
Incorporation of the lepidic component as an additional pathological T descriptor for non-small cell lung cancer: Data from 3335 cases of lung adenocarcinoma.
Lung Cancer. 2024;189:107472.
PubMed Abstract available

GENET SAAM, Visser E, Youssef-El Soud M, Belderbos HNA, et al
Strengths and challenges in current lung cancer care: Timeliness and diagnostic procedures in six Dutch hospitals.
Lung Cancer. 2024;189:107477.
PubMed Abstract available

WU H, Zhang Q, Zhai W, Chen Y, et al
Effectiveness of high-dose third-generation EGFR-tyrosine kinase inhibitors in treating EGFR-mutated non-small cell lung cancer patients with leptomeningeal metastasis.
Lung Cancer. 2024;188:107475.
PubMed Abstract available

VAN ZANDWIJK N, Frank AL
A multidisciplinary review of several aspects of Asbestos-Related Lung Cancer (ARLC).
Lung Cancer. 2024 Jan 17:107474. doi: 10.1016/j.lungcan.2024.107474.
PubMed

PAZ-ARES L, Goto Y, Wan-Teck Lim D, Halmos B, et al
Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase
Lung Cancer. 2024;189:107451.
PubMed Abstract available

NORITAKE O, Nakamura S, Kinoshita F, Aokage K, et al
Prognostic impact of adjuvant therapy for cisplatin-unfit patients with non-small-cell lung cancer: A multicenter analysis.
Lung Cancer. 2024;188:107470.
PubMed Abstract available

CHIANG CL, Huang HC, Luo YH, Shen CI, et al
Clinical utility of immunohistochemical subtyping in patients with small cell lung cancer.
Lung Cancer. 2024;188:107473.
PubMed Abstract available

ZHAO S, Ma Y, Liu L, Fang J, et al
Ningetinib plus gefitinib in EGFR-mutant non-small-cell lung cancer with MET and AXL dysregulations: A phase 1b clinical trial and biomarker analysis.
Lung Cancer. 2024;188:107468.
PubMed Abstract available

PASSIGLIA F, Lucia Reale M, Lo Russo G, Pasello G, et al
Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access program.
Lung Cancer. 2024;187:107444.
PubMed Abstract available

MIKUBO M, Tamagawa S, Kondo Y, Hayashi S, et al
Micropapillary and solid components as high-grade patterns in IASLC grading system of lung adenocarcinoma: Clinical implications and management.
Lung Cancer. 2024;187:107445.
PubMed Abstract available

GAO J, Ao Y, Wang S, Chen Z, et al
WHO histological classification and tumor size are predictors of the locally aggressive behavior of thymic epithelial tumors.
Lung Cancer. 2024;187:107446.
PubMed Abstract available

GAO L, Ai X, Lu S
ETV6::NTRK3 gene fusion in a patient with metastatic lung atypical carcinoid successfully treated with repotrectinib: A case report.
Lung Cancer. 2024;187:107443.
PubMed Abstract available

DUMOULIN DW, Douma LH, Hofman MM, van der Noort V, et al
Nivolumab and ipilimumab in the real-world setting in patients with mesothelioma.
Lung Cancer. 2024;187:107440.
PubMed Abstract available

LEBOUILLE-VELDMAN AB, Taros TN, Nawabi NLA, Mekary RA, et al
Brief report on the efficacy of sotorasib in KRAS-Mutated NSCLC patients with brain metastases.
Lung Cancer. 2024;187:107425.
PubMed Abstract available

December 2023

CHENG Y, Wu L, Huang D, Wang Q, et al
Myeloprotection with trilaciclib in Chinese patients with extensive-stage small cell lung cancer receiving chemotherapy: Results from a randomized, double-blind, placebo-controlled phase III study (TRACES).
Lung Cancer. 2023;188:107455.
PubMed Abstract available

SAKATA Y, Saito G, Sakata S, Oya Y, et al
Corrigendum to "Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT-EP)" [Lung Cancer 186 (2023) 107426].
Lung Cancer. 2023 Dec 29:107450. doi: 10.1016/j.lungcan.2023.107450.
PubMed

PETERS S, Trigo J, Besse B, Moreno V, et al
Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval >/=30 days and without central nervous metastases.
Lung Cancer. 2023;188:107448.
PubMed Abstract available

TAKAM KAMGA P, Mayenga M, Sebane L, Costantini A, et al
Colony stimulating factor-1 (CSF-1) signalling is predictive of response to immune checkpoint inhibitors in advanced non-small cell lung cancer.
Lung Cancer. 2023;188:107447.
PubMed Abstract available

STUART CM, Dyas AR, Bronsert MR, Velopulos CG, et al
The Effect of Social Vulnerability on Initial Stage and Treatment for Non-Small Cell Lung Cancer.
Lung Cancer. 2023;188:107452.
PubMed Abstract available

GRIDELLI C, Peters S, Mok T, Garassino M, et al
Face to face among different chemo-immunotherapy combinations in the first line treatment of patients with advanced non-small cell lung cancer: Results of an international expert panel meeting by the italian association of thoracic oncology (AIOT).
Lung Cancer. 2023;187:107441.
PubMed Abstract available

CHO BC, Chiu CH, Massarelli E, Buchschacher GL, et al
Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer.
Lung Cancer. 2023;188:107442.
PubMed Abstract available

WANG L, Diao M, Zhang Z, Jiang M, et al
Comparison of the somatic genomic landscape between central- and peripheral-type non-small cell lung cancer.
Lung Cancer. 2023;187:107439.
PubMed Abstract available

CAVAZZONI A, Digiacomo G, Volta F, Alfieri R, et al
PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC).
Lung Cancer. 2023;187:107438.
PubMed Abstract available

NASH J, Brims F
International standards of care in thoracic oncology: A narrative review of clinical quality indicators.
Lung Cancer. 2023;186:107421.
PubMed Abstract available

AKRAM F, Wolf JL, Trandafir TE, Dingemans AC, et al
Artificial intelligence-based recurrence prediction outperforms classical histopathological methods in pulmonary adenocarcinoma biopsies.
Lung Cancer. 2023;186:107413.
PubMed Abstract available

LIU Z, Wu Q, Li W, Li P, et al
A novel intergenic (between REG3A and CTNNA2-AS1)-ALK fusion responds to alectinib in lung adenocarcinoma.
Lung Cancer. 2023;186:107386.
PubMed Abstract available

LINGLING X, Maoxi C, Wei Y, Jieting Z, et al
Transformation of NSCLC to SCLC harboring EML4-ALK fusion with V1180L mutation after alectinib resistance and response to lorlatinib: A case report and literature review.
Lung Cancer. 2023;186:107415.
PubMed Abstract available

SCHMALZ L, Bloomer C, Zhang W, Petty W, et al
Durable response to amivantamab in treatment refractory NSCLC harboring EGFR and complex MET mutations: A case report.
Lung Cancer. 2023;186:107400.
PubMed Abstract available

YIN X, Li J, Chen B, Liu K, et al
The predictive value of (18)F-FDG PET/CT combined with inflammatory index for major pathological reactions in resectable NSCLC receiving neoadjuvant immunochemotherapy.
Lung Cancer. 2023;186:107389.
PubMed Abstract available

SUN J, Zhang L, Hu B, Du Z, et al
Deep learning-based solid component measuring enabled interpretable prediction of tumor invasiveness for lung adenocarcinoma.
Lung Cancer. 2023;186:107392.
PubMed Abstract available

November 2023

SCHULER A, Huser J, Schmid S, Schar S, et al
Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study.
Lung Cancer. 2023;187:107427.
PubMed Abstract available

SAKATA Y, Saito G, Sakata S, Oya Y, et al
Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting (OSI-FACT-EP).
Lung Cancer. 2023;186:107426.
PubMed Abstract available

LIVANOU ME, Syrigos NK, Montgomery A, Moeckel C, et al
Eligibility for screening with low-dose CT in a real-world cohort of patients with lung cancer in Greece: A brief report.
Lung Cancer. 2023;186:107424.
PubMed Abstract available

GARON EB, Cho BC, Luft A, Alatorre-Alexander J, et al
Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON).
Lung Cancer. 2023;186:107422.
PubMed Abstract available

KOCHER WULFECK M, Plesner S, Herndon JE 2nd, Christensen JD, et al
Characterizing Lung-RADS category 4 lesions in a university lung cancer screening program.
Lung Cancer. 2023;186:107420.
PubMed Abstract available

MAJEM M, Basch E, Cella D, Garon EB, et al
Understanding health-related quality of life measures used in early-stage non-small cell lung cancer clinical trials: A review.
Lung Cancer. 2023;187:107419.
PubMed Abstract available

KATO T, Casarini I, Cobo M, Faivre-Finn C, et al
Targeted treatment for unresectable EGFR mutation-positive stage III non-small cell lung cancer: Emerging evidence and future perspectives.
Lung Cancer. 2023;187:107414.
PubMed Abstract available

STOCKHAMMER P, Baumeister H, Ploenes T, Bonella F, et al
Krebs von den Lungen 6 (KL-6) is a novel diagnostic and prognostic biomarker in pleural mesothelioma.
Lung Cancer. 2023;185:107360.
PubMed Abstract available

October 2023

LIU SV, Mok TSK, Nabet BY, Mansfield AS, et al
Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide.
Lung Cancer. 2023;186:107418.
PubMed Abstract available

MANGLAVITI S, Bini M, Apollonio G, Zecca E, et al
High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors.
Lung Cancer. 2023;186:107417.
PubMed Abstract available

FURUNE S, Ando Y
Comment on: Carboplatin and irinotecan (CI) vs. Carboplatin and etoposide (CE) for the treatment of extended-stage small-cell lung cancer in an elderly population: A phase II/III randomized control trial.
Lung Cancer. 2023;186:107416.
PubMed

KIM W, Lee SC, Lee WR, Chun S, et al
The effect of the introduction of the national lung cancer screening program on short-term mortality in Korea.
Lung Cancer. 2023;186:107412.
PubMed Abstract available

HUANG S, Wu J, Li S, Li X, et al
Evaluation of combined pathological responses in primary tumor and lymph nodes following neoadjuvant chemoimmunotherapy in non-small cell lung cancer.
Lung Cancer. 2023;186:107401.
PubMed Abstract available

DEHEM A, Mazieres J, Chour A, Guisier F, et al
Characterization of 164 patients with NRAS mutated non-small cell lung cancer (NSCLC).
Lung Cancer. 2023;186:107393.
PubMed Abstract available

MORETTI A, Kovacevic B, Vilmann P, Annema JT, et al
Performance of EUS-FNA and EUS-B-FNA for the diagnosis of left adrenal glands metastases in patients with lung cancer: A systematic review and meta-analysis.
Lung Cancer. 2023;186:107391.
PubMed Abstract available

RYU WK, Yong SH, Lee SH, Gwon HR, et al
Usefulness of bronchial washing fluid for detection of EGFR mutations in non-small cell lung cancer.
Lung Cancer. 2023;186:107390.
PubMed Abstract available

RUGGIRELLO M, Valsecchi C, Ledda RE, Sabia F, et al
Long-term outcomes of lung cancer screening in males and females.
Lung Cancer. 2023;185:107387.
PubMed Abstract available

LIM TKH, Skoulidis F, Kerr KM, Ahn MJ, et al
KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing.
Lung Cancer. 2023;184:107293.
PubMed Abstract available

HO H, Yu SL, Chen HY, Yuan SS, et al
Whole exome sequencing and MicroRNA profiling of lung adenocarcinoma identified risk prediction features for tumors at stage I and its substages.
Lung Cancer. 2023;184:107352.
PubMed Abstract available

MATSUNAGA T, Suzuki K, Hattori A, Fukui M, et al
A problem with clinical T factor in the 8th TNM edition: Prognosis and EGFR mutation status of small sized lung cancers with difficulty to measure the diameter of solid component in part-solid tumor.
Lung Cancer. 2023;184:107354.
PubMed Abstract available

LINDBERG K
Balancing tumour control probability and toxicity in SBRT of ultra-central lung tumours - One step forward.
Lung Cancer. 2023;184:107343.
PubMed

GOTO E, Takamochi K, Kishikawa S, Hayashi T, et al
Stepwise progression of invasive mucinous adenocarcinoma based on radiological and biological characteristics.
Lung Cancer. 2023;184:107348.
PubMed Abstract available

QI R, Fu X, Yu Y, Xu H, et al
Efficacy and safety of re-challenging 160 mg furmonertinib for advanced NSCLC after resistance to third-generation EGFR-TKIs targeted agents: A real-world study.
Lung Cancer. 2023;184:107346.
PubMed Abstract available

SEKER-CIN H, Tay TKY, Kazdal D, Kluck K, et al
Analysis of rare fusions in NSCLC: Genomic architecture and clinical implications.
Lung Cancer. 2023;184:107317.
PubMed Abstract available

ZIRANU P, Ferrari PA, Guerrera F, Bertoglio P, et al
Clinical score for colorectal cancer patients with lung-limited metastases undergoing surgical resection: Meta-Lung Score.
Lung Cancer. 2023;184:107342.
PubMed Abstract available

YEUNG V, Zaemes J, Yeh J, Giancarlo C, et al
High levels of expression of Trop-2 in thymic epithelial tumors.
Lung Cancer. 2023;184:107324.
PubMed Abstract available

GEMINE RE, Davies GR, Lanyon K, Rees SE, et al
Quitting smoking improves two-year survival after a diagnosis of non-small cell lung cancer.
Lung Cancer. 2023;186:107388.
PubMed Abstract available

September 2023

NUTZINGER J, Bum Lee J, Li Low J, Ling Chia P, et al
Management of HER2 alterations in non-small cell lung cancer - The past, present, and future.
Lung Cancer. 2023;186:107385.
PubMed Abstract available

CHOW R, McMillan MT, Simone CB 2nd
Microwave Ablation for Early-Stage Non-Small Cell Lung Cancer: Don't Put the Cart Before the Stereotactic Horse.
Lung Cancer. 2023;185:107382.
PubMed

ZHANG Y, Li N, Dong Y, Wang W, et al
Spatial microenvironment heterogeneity in therapy-naive lung cancer: A concept with more attention needed.
Lung Cancer. 2023;185:107384.
PubMed

DAGOGO-JACK I, Kiedrowski LA, Lennerz JK
Molecular heterogeneity and co-altered genes in MET-amplified ALK-positive lung cancer: Implications for MET targeted therapy.
Lung Cancer. 2023;186:107383.
PubMed Abstract available

FALCHERO L, Guisier F, Darrason M, Boyer A, et al
Long-term effectiveness and treatment sequences in patients with extensive stage small cell lung cancer receiving atezolizumab plus chemotherapy: Results of the IFCT-1905 CLINATEZO real-world study.
Lung Cancer. 2023;185:107379.
PubMed Abstract available

KRAMER T, Kuijvenhoven JC, von der Thusen J, Cohen D, et al
Endobronchial ultrasound in diagnosing and staging of lung cancer by Acquire 22G TBNB versus regular 22G TBNA needles: A randomized clinical trial.
Lung Cancer. 2023;185:107362.
PubMed Abstract available

PARRA-MEDINA R, Pablo Castaneda-Gonzalez J, Montoya L, Paula Gomez-Gomez M, et al
Prevalence of oncogenic driver mutations in Hispanics/Latin patients with lung cancer. A systematic review and meta-analysis.
Lung Cancer. 2023;185:107378.
PubMed Abstract available

GARCIA CAMPELO MR, Wan Y, Lin HM, Chen T, et al
Q-TWiST analysis of survival benefits with brigatinib versus crizotinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer based on results of the ALTA-1L trial.
Lung Cancer. 2023;185:107376.
PubMed Abstract available

BOESCHEN M, Kuhn CK, Wirtz H, Seyfarth HJ, et al
Comparative bioinformatic analysis of KRAS, STK11 and KEAP1 (co-)mutations in non-small cell lung cancer with a special focus on KRAS G12C.
Lung Cancer. 2023;184:107361.
PubMed Abstract available

PORTA C, Pradelli L, Sicari E, Castellani S, et al
Liquid biopsy comprehensive genomic profiling of lung cancer in the Italian population: A real-world experience.
Lung Cancer. 2023;185:107359.
PubMed Abstract available

HAN D, Zhu Y, Choudhry AA, Cheng J, et al
Association of telomere length with risk of lung cancer: A large prospective cohort study from the UK Biobank.
Lung Cancer. 2023;184:107358.
PubMed Abstract available

August 2023

ZHAO Y, Ma Y, Fan Y, Zhou J, et al
A multicenter, open-label phase Ib/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non-small-cell lung cancer (AK104-202 study).
Lung Cancer. 2023;184:107355.
PubMed Abstract available

KU HY, Lin SM, Wang CL, Lo YC, et al
Impact of pathological nodal staging and tumour differentiation on survival and postoperative radiotherapy in completely resected stage IIIA Non-small-cell lung cancer.
Lung Cancer. 2023;184:107357.
PubMed Abstract available

ZENG L, Zhou Y, Xu Q, Huang Z, et al
Dynamic cytokines signature predicts survival outcome from severe Immune-related hepatitis with PD-1/PD-L1 blockade in lung cancer.
Lung Cancer. 2023;184:107350.
PubMed Abstract available

LEFEBVRE AM, Adam J, Nicolazzi C, Larois C, et al
The search for therapeutic targets in lung cancer: Preclinical and human studies of carcinoembryonic antigen-related cell adhesion molecule 5 expression and its associated molecular landscape.
Lung Cancer. 2023;184:107356.
PubMed Abstract available

BOZORGMEHR F, Muller A, Rawluk J, Sianidou M, et al
Immune checkpoint inhibitors in non-small cell lung cancer - When should we dare to stop treatment?
Lung Cancer. 2023;184:107340.
PubMed Abstract available

LEVALLET G, Dubois F, Elie N, Creveuil C, et al
VEGFR2 and CD34 expression associated with longer survival in patients with pleural mesothelioma in the IFCT-GFPC-0701 MAPS phase 3 trial.
Lung Cancer. 2023;182:107287.
PubMed Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum